



NIH PUBLIC ACCESS

Author Manuscript

J Child Psychol Psychiatry. Author manuscript; available in PMC 2012 April 1.

Published in final edited form as:

J Child Psychol Psychiatry. 2011 April ; 52(4): 442–475. doi:10.1111/j.1469-7610.2011.02380.x.

Transgenic Mouse Models of Childhood Onset Psychiatric Disorders

Holly R. Robertson^{1,2} and Guoping Feng^{1,2}¹Duke University, Neurobiology Department Durham, N.C.²Massachusetts Institute of Technology, Brain and Cognitive Sciences Department Cambridge, M.A.

Abstract

Childhood onset psychiatric disorders, such as Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Mood Disorders, Obsessive Compulsive Spectrum Disorders (OCS), and Schizophrenia (SZ), affect many school age children leading to a lower quality of life, including difficulties in school and personal relationships that persists into adulthood. Currently, the causes of these psychiatric disorders are poorly understood resulting in difficulty diagnosing affected children, and insufficient treatment options. Family and twin studies implicate a genetic contribution for ADHD, ASD, Mood Disorders, OCS, and SZ. Identification of candidate genes and chromosomal regions associated with a particular disorder provide targets for directed research, and understanding how these genes influence the disease state will provide valuable insights for improving the diagnosis and treatment of children with psychiatric disorders. Animal models are one important approach in the study of human diseases, allowing for the use of a variety of experimental approaches to dissect the contribution of a specific chromosomal or genetic abnormality in human disorders. While it is impossible to model an entire psychiatric disorder in a single animal model, these models can be extremely valuable in dissecting out the specific role of a gene, pathway, neuron subtype, or brain region in a particular abnormal behavior. In this review we discuss existing transgenic mouse models for childhood onset psychiatric disorders. We compare the strength and weakness of various transgenic animal models proposed for each of the common childhood onset psychiatric disorders, and discuss future directions for the study of these disorders using cutting-edge genetic tools.

Childhood onset psychiatric disorders including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Mood Disorders, Obsessive Compulsive Spectrum Disorders (OCS), and Schizophrenia (SZ) affect many school age children. These children typically have a lower quality of life, including difficulties in school and personal relationships, and these problems persist into adulthood. Additionally, the treatment and support of these individuals causes severe financial and social burdens on society. Currently, the causes of these psychiatric disorders are poorly understood. This lack of knowledge results in difficulty diagnosing affected children, and insufficient treatment options.

Family and twin linkage studies implicate a genetic contribution for ADHD, ASD, Mood Disorders, OCS, and SZ (Hudziak and Faraone, 2010). In some cases single, rare genetic mutations lead to childhood onset psychiatric disorders (Hudziak and Faraone, 2010). Additionally, there is a hypothesis that other cases are multigenic, with many genes

contributing small effects leading to the overall disease state (Hudziak and Faraone, 2010). Developmental and environmental factors can also influence the severity of symptoms observed in affected individuals leading to a “spectrum” of behaviors (Dick et al., 2010). Identification of candidate genes and chromosomal regions associated with a particular disorder provide targets for directed research, and understanding how these genes influence the disease state will provide valuable information for improving the diagnosis and treatment of children with psychiatric disorders.

Animal models are one method commonly utilized in the study of human diseases. Specifically, animal models can overcome many of the confounding factors that limit research in human patients including genetic variability and environmental diversity. Some benefits of using transgenic mice to model human diseases include genetically homogeneous populations, greater control over environmental conditions, shorter time between generations, pharmacological studies, and the opportunity for genetic manipulations. The generation of transgenic mouse models can therefore allow for a controlled approach in evaluating the consequences of a specific chromosomal or genetic abnormality observed in human patients.

There are however limitations to using animal models to study psychiatric disorders. Most importantly, there are many behaviors of psychiatric disorders that are currently impossible to evaluate in a mouse model. For example, obsessive thinking in OCD, and hallucinations in SZ cannot be assessed in mice. Thus, researchers are limited to modeling behaviors of psychiatric disorders that can be assessed in a mouse including hyperactivity, social interactions, anxiety, and some types of learning and memory (Crawley, 2007). However, it is important to note that even behaviors that can be assessed in a mouse are not an exact replica of human behavior. At best, we can make correlations between the observed mouse behavior and known human behaviors in these disorders.

It is also impossible to model an entire psychiatric disorder in a single animal model. Psychiatric disorders are complex disorders, and current technology cannot expect to encompass the entirety of such a complex disorder within a single model (Laporte et al., 2008). A more realistic approach is to model a specific behavior, or single genetic mutation associated with a disorder in an individual model. These models can then be used to dissect out the specific role of a gene, pathway, neuron subtype, or brain region in a particular behavior.

Establishing a transgenic mouse as a model of a psychiatric disorder requires face, construct, and predictive validity. Face validity refers to the resemblance of the mouse model phenotype to the symptoms of the human disorder. In some cases, rodent behaviors can be directly correlated to human symptoms. For example, pre-pulse inhibition (PPI), a test of sensory-motor gating, can be evaluated in both humans and rodents (Geyer, 2008). Other behaviors in mice are correlative to human behaviors. For example, tests to show anxiety-like behaviors in a mouse include time spent in the open section of the elevated plus maze and emergence to light in the light dark emergence test. These particular behaviors are not observed in humans with anxiety; however the observation of the behavior in the mouse is sufficient to draw a positive correlation in some cases. Table 1 lists behavior tests commonly used in characterizing mouse models of psychiatric disorders.

Construct validity refers to similarities in the mouse model to the underlying cause of the human disorder. Gene association and linkage studies can implicate certain genes which are then targeted in transgenic mouse models and therefore partially address construct validity. Finally, predictive validity refers to the expected response in the mouse model to treatments

as observed in human patients. Establishing predictive validity is helpful for evaluating the potential of future novel therapies for a particular disorder.

In this review we will discuss transgenic mouse models for childhood onset psychiatric disorders. We will introduce the currently proposed transgenic animal models for common childhood onset psychiatric disorders, and discuss future directions for the study of these disorders using cutting-edge genetic tools. We apologize that due to page limitations, we were unable to list all relevant references in this review.

I. Attention Deficit Hyperactivity Disorder

ADHD is one of the most prevalent childhood psychiatric disorders affecting an estimated 8–12% of school age kids (Biederman and Faraone, 2005). ADHD was originally described by Bradley et al. in the 1930s. They observed that treatment with sedatives paradoxically resulted in increased activity in children with what they called minimal brain damage (now called ADHD) (Bradley, 1937). Additionally, administration of stimulants to these children resulted in normalized behavior (Bradley, 1937). Today ADHD is characterized by hyperactivity, impaired sustained attention, impulsivity, and distractibility (APA, 2000).

Family, twin, and adoption studies confirm genetics play an important role in susceptibility to ADHD (Sharp et al., 2009). Genome wide linkage analysis studies identified peak regions on chromosome 3, 4, 5, 6, 7, 9, 10, 11, 15, 16,17, and 20 (Sharp et al., 2009). Genetic studies of candidate genes within these ADHD linkage regions found association of genes involving the dopamine, serotonin, glutamatergic and adrenergic systems (Sharp et al., 2009).

Many of the current animal models of ADHD are pharmacological or environmental models, which will not be discussed in this review (For an extensive review of these models see (Kostrzewa et al., 2008)). Here we will focus on transgenic mouse models of ADHD.

DAT KO

The dopamine transporter (DAT) facilitates the recycling of extracellular dopamine (DA) (Giros et al., 1996). DAT is a major target for psychostimulants including cocaine and amphetamine as found through pharmacological studies (Giros and Caron, 1993, Heikkila et al., 1975). In addition, genetic studies show polymorphisms in the *DAT* gene are associated with increased risk of ADHD (Xu et al., 2009), although there are also studies that fail to identify an association (Langley et al., 2005).

Generation of DAT null (DAT KO) mice led to overall and specific growth disorders, such as dwarfism, as well as increased premature death (Bosse et al., 1997). Behavior studies show DAT KO mice are more active in home cage environments and novel environments as found in the open field test, and show defects in spatial memory as measured by performance in the radial arm test (Gainetdinov et al., 1999). Administration of psychostimulants (methylphenidate, dextroamphetamine, and cocaine) attenuates hyperactivity in DAT KO mice (Gainetdinov et al., 1999). The ability of psychostimulants to attenuate hyperactivity in DAT KO mice suggests a possible secondary mechanism of action for psychostimulants, possibly through their effect on other monoamine transporters (Hall et al., 2009, Riddle et al., 2007).

Administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine and the nonselective 5-HT receptor agonist quipazine blocks hyperactivity in DAT KO mice (Gainetdinov et al., 1999). The selective 5-HT_{2A} R antagonist M100907 also reduced hyperactivity in DAT KO mice (Barr et al., 2004). This effect of serotonin on hyperactivity may be mediated by glutamatergic signaling, as blockade of NMDARs prevented the

inhibitory effects on locomotor activity in DAT KO mice by psychostimulants and serotonin drugs (Gainetdinov et al., 2001). In particular, glutamatergic and dopaminergic signaling in the cortico-striatal pathway appears to be important for effects of hyperactivity in DAT KO mice (Gainetdinov et al., 2001). There are some cases of adults with ADHD responding positively to duloxetine, a selective serotonin norepinephrine reuptake inhibitor (SSNRI) (Tourjman and Bilodeau, 2009). However, currently few studies have explored the effectiveness of SSRIs and other antidepressants in ADHD (Verbeeck et al., 2009).

DAT KD

The DAT KO (previously described above) had developmental deficits and high levels of premature death with only 68% survival at 10 weeks of age in knockout animals (Bosse et al., 1997). Zhuang et al thought to avoid these development issues by creating a DAT knockdown (DAT KD) by introducing an additional 4Kb of sequence in the promoter region resulting in decreased transcription to 10% of the normal DAT levels. This approach successfully prevented the growth defects and high mortality rates observed in the DAT KO (Zhuang et al., 2001).

DAT KD mice exhibit hyperactive behaviors like the DAT KO mice that are alleviated by administration of amphetamines or valproate, treatments for ADHD and mania respectively (Ralph-Williams et al., 2003, Zhuang et al., 2001). Additionally, DAT KD mice show increased motivation for food rewards (Pecina et al., 2003). Specifically, DAT KD mice had higher learning acquisition and greater incentive performance for a sweet reward in a runway test (Pecina et al., 2003). The increased “wanting” in the DAT KD mouse is likened to drug seeking in models of addiction in humans. However, the increased focus on obtaining the sweet reward and how this relates to a possible contradiction of inattention in ADHD has not been addressed.

Another study looked at instrumental learning in the DAT KD mice (Yin et al., 2006). This study found DAT KD mice do not have impaired learning abilities. Interestingly though, the DAT KD mice did show a deficit in selectivity of cue control during Pavlovian training. DAT KD mice would enter the food magazine before the conditional stimulation (CS) as frequently as during the CS even though no reward was present in the magazine before the CS (Yin et al., 2006). WT mice showed clear discrimination by entering significantly more frequently during the CS than the pre-CS. The authors suggest this lack of discrimination could also represent higher “wanting” (Yin et al., 2006). How this higher “wanting” and decreased discrimination behavior might relate to impulsivity in ADHD has yet to be explored. (See also OCSD)

Coloboma Mice

The coloboma mouse was generated by neutron irradiation (Searle, 1966), which resulted in a mutation on Chromosome 2 affecting the genes *SNAP-25* (synaptosomal-associated protein 25), *PCLB-1* (phospholipase c beta-1), and *Jag1* (Jagged 1) (Hess et al., 1994). The coloboma mouse was characterized as a model of ADHD when increased spontaneous activity compared to control animals was observed in the open field test (Hess et al., 1992). Some human genetic studies show an association of *SNAP-25* to ADHD (Forero et al., 2009). However, other studies have failed to associate *SNAP-25* and ADHD (Hess et al., 1995). *SNAP-25* mutant mice show deficits in PPI, however their ataxia precludes the ability to assess hyperactivity and other behaviors characteristic of ADHD (Jeans et al., 2007). Therefore, the current *SNAP-25* mouse model cannot confirm *SNAP-25* is the gene causing the ADHD-like behaviors in the Coloboma mice.

Coloboma pups exhibit delayed neurodevelopmental milestones, hypersensitivity to touch, and persistent head bobbing which is not observed in control mice (Heyser et al., 1995). Unfortunately, these mice also have eye dysmorphia, delayed lens attachment, and microphthalmia (Theiler and Varnum, 1981). Therefore evaluation of behavioral tests in these mice must be interpreted cautiously.

Altered DA and norepinephrine (NE) concentration is found in the striatum and the Nucleus Acumbens (NAc) of coloboma mice, which may be a result of altered presynaptic function (Jones et al., 2001). Mutations in the *SNAP-25* gene may contribute to this phenotype as this protein is involved in docking synaptic vesicles (Jones et al., 2001). The striatum and NAC play important roles in regulating motor activity, therefore a phenotype of hyperactivity in these mice is consistent with altered transmission in these brain regions (Wachtel et al., 1979). Amphetamine administration normalizes hyperactivity in coloboma mice, which is consistent with treatment of ADHD patients (Hess et al., 1996). A recent study shows the effect of amphetamine on hyperactivity is mediated specifically through the dopamine 2 (D2) receptor subtype (Fan et al., 2010). Methylphenidate, another psychostimulant, however results in dose-dependent increases in locomotor activity (Hess et al., 1996). The difference in response to these psychostimulants is proposed to be likely due to the difference in mechanistic action between the two drugs (Hess et al., 1996). Specifically, psychostimulants are categorized on their sensitivity to pretreatment with reserpine, a drug that disrupts vesicular release by depleting vesicular stores of catecholamines. Amphetamine is not inhibited by pretreatment with reserpine, and therefore is thought to increase synaptic DA independent of vesicular release. Methylphenidate is inhibited by pretreatment with reserpine, and is therefore sensitive to vesicle depletion. The authors suggest that the opposing effects of amphetamine and methylphenidate may highlight a presynaptic defect involving SNAP-25 in coloboma mice, however the exact mechanism underlying this effect has not been explored (Hess et al., 1996).

Decreasing NE transmission by blocking the α -2C adrenergic receptor, or decreasing NE levels with systemic administration of DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride), also led to decreased hyperactivity in the coloboma mice (Bruno and Hess, 2006, Jones and Hess, 2003). This evidence further suggests the NE system plays a role in affecting hyperactivity.

Coloboma mice also exhibit inattention and impulsivity, two additional characteristics of ADHD. Specifically, coloboma mice have disrupted latent inhibition (LI), and show impaired performance in the delayed reinforcement paradigm (Bruno et al., 2007). Thus, coloboma mice demonstrate several characteristics associated with ADHD though physical defects limit the usefulness of this model.

Other ADHD Models

Some ADHD patients show evidence of subtle reductions in the thickness of the anterior and posterior corpus callosum, a structure connecting the two hemispheres of the brain and possibly involved in the control of sustained attention (Baumgardner et al., 1996). The Acallosal I/LN J mouse model is an inbred mouse line that completely lacks the corpus callosum. This mouse shows poor impulse control and learning difficulties in the Y-maze and avoidance test, and hyperactivity in the open field (Magara et al., 2000). Human cases with altered corpus callosum are associated with disorders that have both physical and mental characteristics that are unrelated to ADHD (Paul et al., 2007). Therefore, the role of the corpus callosum in human cases of ADHD might be difficult to assess due to the comorbidity of these disorders.

Thyroid hormones are critical for normal brain development, and abnormal thyroid hormone levels in utero have been linked to ADHD like behaviors (Hauser et al., 1998). Resistance to thyroid hormone (RTH) is caused by mutations in thyroid receptor β (Thrb), which results in a failure to down-regulate thyroid stimulating hormone (TSH). 70% of children diagnosed with RTH syndrome are also diagnosed with ADHD (Siesser et al., 2006). Thus, exploring the potential role of Thrb involvement in ADHD is an intriguing question. Generation of a transgenic mouse model that expresses a mutated human Thrb, Thrb knock-in (Thrb KI), results in hyperactivity in the open field test, impulsivity in the delayed reinforcement test, and inattentiveness in the reaction-time task selectively in male mice in some test conditions (Siesser et al., 2006). However, to date it is unclear how these sex differences and conditional responses may relate to ADHD in humans.

Casein Kinase 1 (CK1) is a conserved family of Ser/Thr kinases important for many cellular processes including cell signaling, circadian rhythm, and cellular trafficking (Knippschild et al., 2005). The CK1 δ isoform is highly enriched in the brain (Zhou et al., 2010), and CK1 regulates the phosphorylation state of DARPP-32 (dopamine and c-AMP regulated phosphoprotein MW 32 kDa), an important, striatum expressed, protein phosphatase inhibitor which integrates synaptic inputs from various sources including glutamatergic and dopaminergic inputs (Svenningsson et al., 2004). Thus, DARPP-32 is an important modulator of the Cortico-Striato-Thalamic-Cortico (CSTC) loop. Overexpression of CK1 δ (CK1 δ OE) in the forebrain led to down-regulation of dopamine receptors, increased hyperactivity in the open field, and decreased anxiety in the elevated plus maze and the novelty suppressed feeding paradigm, which measures the latency to initiate eating in a novel environment (Zhou et al., 2010). This hyperactivity was attenuated by treatment with methylphenidate, sub-maximal doses of amphetamine, the dopamine 1 (D1)R agonist SKF81297, and the D2R agonist quinprole (Zhou et al., 2010). Thus, CK1 δ OE is proposed as a potential new model for ADHD.

II. Autism Spectrum Disorder

ASD is a developmental disorder occurring in as many as 1:150 children, with males four times more likely to be diagnosed than females (CDC, 2009). Clinical diagnosis criteria for ASD are aberrant reciprocal social interactions, deficits in communication, and stereotyped repetitive behavior with restricted interest (APA, 2000). Currently, there are no effective pharmacological treatments for ASD.

Family and twin studies show that ASD is highly heritable (O'Roak and State, 2008). Additionally, linkage and association studies have identified several potential susceptibility loci and multiple candidate genes potentially involved in ASD (Abrahams and Geschwind, 2008). Advances in detection of copy number variations (CNVs), rare deletions, duplications, and single nucleotide polymorphisms (SNPs) identified cases of ASD with rare, single locus genetic changes that can either be inherited or de novo (Marshall et al., 2008). Finally, there is a high incidence of ASD symptoms in individuals with monogenic disorders such as Rett Syndrome, Fragile X, Angelman Syndrome, and Down's Syndrome (Moss and Howlin, 2009). Thus ASD arises from many different genetic sources that are in some cases further influenced by environmental factors leading to high levels of variability in the severity of behaviors in affected individuals (Herbert et al., 2006).

There are several mouse models of ASD currently being investigated including environmental, pharmacological, and inbred strains that will not be covered by the scope of this review (Benno et al., 2009, Kuwagata et al., 2009, Marin et al., 2008, Patterson, 2009, Singer et al., 2009). In this review we will focus on transgenic mouse models thought to have characteristics of ASD.

Developmental Disorders with Autism-like Features

Several developmental disorders with known monogenetic causes display autistic characteristics (Reiss, 2009). Therefore, mouse models targeting these disorders may be useful in discovering brain circuits involved in the expression of autism related behaviors. While one must be cautious of non-autism related physical and mental handicaps associated with these disorders, these models are still very useful in the study of autism.

Fragile X—Fragile X is a genetic disorder that predominantly affects males and is caused by a mutation of the *Fmr1* (Fragile X mental retardation 1) gene resulting in the loss of fragile X mental retardation protein (FMRP) (Oostra, 1996). Characteristics of Fragile X include mental retardation, facial dysmorphology, macroorchidism, seizures, and autistic-like behaviors (Garber et al., 2008).

Transgenic mouse models of Fragile X show increased susceptibility to limbic seizures (Qiu et al., 2009). Additionally, deficits in spatial learning by radial arm maze, deficits in object recognition, deficits in acquiring lever-press/avoidance, and deficits in learning in the Morris water maze were observed in FMRP null mice (Brennan et al., 2006, D'Hooge et al., 1997, Mineur et al., 2002, Ventura et al., 2004). Tests of the effect of loss of FMRP on social behaviors resulted in conflicting data. Some groups identified deficits in social approach and social anxiety using the three-chamber social approach test (Mineur et al., 2006, Liu and Smith, 2009), while others found equal or increased social approach (McNaughton et al., 2008, Spencer et al., 2005). Currently, it is not clear why there are contradictory results. Differences in experimental design, controls, and animal age are potential reasons (Brodkin, 2008).

FMRP null mice have increased dendritic spine length and altered spine morphology similar to changes observed in patients with Fragile X and ASD (Irwin et al., 2000). FMRP is an mRNA binding protein that associates with polyribosomes, including dendritic polysomes, and is thought to be involved in translational regulation of specific mRNAs (Brown et al., 2001). FMRP null mice show deficits in cortical long-term potentiation (LTP), and enhanced mGluR dependent long-term depression (LTD) (Nosyreva and Huber, 2006, Zhang et al., 2009). Importantly, FMRP is hypothesized to repress mRNA translation in response to mGluR5 activation (Bear et al., 2004). In support of this hypothesis, transgenic mice with 50% reduction of mGluR5 on the FMRP null background corrected many of the phenotypes observed in the FMRP null mice including basal protein synthesis, sensitivity to audiogenic seizures, and spine density in cortical pyramidal neurons (Dolen et al., 2007). Also, the mGluR5 antagonist, MPEP, can rescue PPI in FMRP null mice (de Vrij et al., 2008). Additionally, inhibition of p21-activated kinase (PAK), a downstream target of FMRP, also rescues some phenotypes of FMRP null mice. Expression of a dominant negative PAK (dnPAK) in the forebrain corrected dendritic spine morphology, cortical LTP, and hyperactivity and anxiety as measured by the open field test in the FMRP null mice (Hayashi et al., 2007). These studies implicate potential new therapeutic targets in treating fragile X patients.

Rett Syndrome—Another genetic disorder with autistic-like behaviors is Rett syndrome (Nomura, 2005). Rett syndrome is characterized by normal development for the first 6–18 months of life followed by regression of social, language, and cognitive function, and the emergence of stereotyped hand movements, decreased brain growth, and motor impairments (Glaze, 2004). While some cases do see improvement in behavior and communication in later stages of Rett syndrome, there is not a complete return to normal behavior (APA, 2000). Rett syndrome is an X-linked disorder like Fragile X, however Rett syndrome primarily affects females with most males dying either in utero or shortly after birth

(Hoffbuhr et al., 2001). Most cases of Rett syndrome are caused by a mutation in methyl CpG binding protein 2 (Mecp2), a protein that binds to methylated DNA resulting in both gene silencing and activation (Chahrour et al., 2008).

Mecp2 mutant mice exhibit phenotypes similar to behaviors observed in patients with Rett syndrome (Stearns et al., 2007). Generation of Mecp2 null mouse lines led to onset of symptoms around 5–6 weeks of age with neurological characteristics similar to Rett syndrome including motor coordination defects (Guy et al., 2001, Chen et al., 2001a). A truncated mutation of Mecp2 also led to similar onset of characteristic features of Rett syndrome (Shahbazian et al., 2002). Studies to investigate social interactions show mice expressing truncated Mecp2 have reduced social interaction with no effect on social recognition as assessed by the partition test (Moretti et al., 2005). These mice also show deficits in long-term social memory using the social recognition test, deficits in nest building and other home cage behaviors, and impaired learning and memory in the Morris water maze and contextual fear conditioning test (Moretti et al., 2005, Moretti et al., 2006).

A Mecp2 mutant mouse with postnatal loss of expression or forebrain specific deletion still exhibits social interaction deficits in the partition test and resident intruder paradigm suggesting loss of Mecp2 plays a critical role in adult neurons in addition to its role during development (Gemelli et al., 2006, Chen et al., 2001a). Additionally, studies showing that replacement of Mecp2 in adult mice can correct defects in Mecp2 null mice including survival, motor defects, and locomotor defects, suggesting some characteristics of Rett syndrome are not irreversible developmental defects (Guy et al., 2007, Jugloff et al., 2008, Luikenhuis et al., 2004). Both Mecp2 null mice, and mice expressing truncated Mecp2 show decreased numbers of synaptic connections and deficits in synaptic plasticity (Belichenko et al., 2009, Dani and Nelson, 2009, Moretti et al., 2006). Treatment with the growth factors brain derived neurotrophic factor (BDNF) and insulin-like growth factor 1 (IGF-1) ameliorate some of the symptoms of Rett syndrome found in Mecp2 null mice (Chang et al., 2006, Tropea et al., 2009). BDNF and IGF-1 are both known to affect spine morphology through pathways involving phosphoinositide-3-kinase (PI3K) (Zheng and Quirion, 2004). Cerebrolysin (CBL), a drug known to have neuroprotective and neurotrophic activity, can ameliorate symptoms of neurodegeneration and aging, and can also ameliorate dendritic simplification in mice expressing truncated Mecp2 (Doppler et al., 2008). These studies suggest defects in dendritic spine morphology may be a contributing factor in the expression of Rett Syndrome.

15q11–13 Deletion/Duplication—Angelman Syndrome (AS) is a genomically imprinted disorder that is linked to the 15q11–13 region, and displays autistic-like behaviors (Veltman et al., 2005). Imprinted genes show expression from only one inherited copy of a gene, therefore if there is a mutation or deletion of the gene copy that should be expressed, the second copy cannot compensate resulting in loss of function. AS results from loss of the maternal copy of Ube3A (ubiquitin protein ligase E3A), a ubiquitin ligase (Clayton-Smith and Laan, 2003). Interestingly, decreased Ube3A expression has also been observed in a small number of cases of ASD and Rett syndrome (Samaco et al., 2005). Mice with a maternal deficit in Ube3a have enhanced seizure susceptibility, deficits in motor coordination, and reduced spatial learning in the Morris water maze (Miura et al., 2002). Recent studies address how Ube3a may be affecting neurological processes including cognitive impairment. Specifically, these studies show Ube3a plays an important role in experience-dependent plasticity and synapse development (Greer et al., 2010, Yashiro et al., 2009).

15q11–13 also contains several GABA_A receptor (GABR) subunit genes including the *GABRB3*, *GABRA5*, and *GABRG3* genes (DeLorey et al., 2008). GABAergic signaling plays

an important role in brain development (Manent and Represa, 2007), and altered GABAergic signaling is found in some patients with ASD (Blatt, 2005). Additionally, polymorphisms in *GABRB3* have been associated with autism by a linkage and association study (Buxbaum et al., 2002).

Gabrb3 null mice have high rates of neonatal mortality (Homanics et al., 1997). Mice that survive show enhanced seizure susceptibility, abnormal motor coordination, and impaired learning and memory in the contextual fear conditioning and passive avoidance test (DeLorey et al., 1998, Homanics et al., 1997). A later study shows *Gabrb3* KO mice have impaired social interaction in the partition test, and impaired nesting behaviors (DeLorey et al., 2008). *Gabrb3* KO mice are also hyperactive but show stereotyped circling and decreased exploratory behavior in the open field with a novel object, which is suggested as being an index of non-selective attention in this model (DeLorey et al., 2008).

Duplication of the 15q11–13 chromosomal region is also associated with ASD. This duplication is present in up to 5% of ASD cases, and is most commonly maternally derived although evidence for paternally derived duplications is accumulating (Bolton et al., 2004, Dykens et al., 2004, Roberts et al., 2002, Schroer et al., 1998). On the basis of conserved human/mouse linkage, generation of a transgenic mouse carrying a 6.3 Mb duplication of mouse chromosome 7 mirroring the human chromosome 15q11–13 duplication was generated by Nakatani et al. Mice carrying a paternally derived 15q11–13 duplication results in poor social interaction in the three chamber social approach test, behavioral inflexibility in the Morris water maze and Barnes maze test, and abnormal ultrasonic vocalizations in both neonatal pups separated from their mother and adult mice in the resident intruder test (Nakatani et al., 2009). These mice also exhibit anxiety as measured by the elevated plus maze, and depression as measured by the forced swim test (Nakatani et al., 2009). However, mice carrying a maternally derived duplication did not show any behavioral differences when compared to WT mice (Nakatani et al., 2009). Thus, while in humans the 15q11–13 duplication is usually maternally derived, these mice do mimic a chromosomal duplication found in human ASD patients, and several autistic-like behaviors are present in the paternally derived mice suggesting this could be a good model for studying mechanisms in ASD-like behavior.

Other Developmental Disorders with Autism-like Features—Other developmental disorders with autistic-like phenotypes include tuberous sclerosis (TSC), Smith-Lamli-Ortiz Syndrome (SLOS), and Down's Syndrome (Moss and Howlin, 2009). A mouse model of TSC, *Tsc1* conditional knockout, has enhanced cortical excitability, abnormal spine density and morphology, and seizures (Meikle et al., 2007). SLOS is a neurodevelopmental disorder associated with high rates of autism (Sikora et al., 2006). SLOS is caused by mutations in *DHCR7* (7-dehydrocholesterol reductase), which leads to disruption of cholesterol formation (Fitzky et al., 1998). Cholesterol levels have been shown to be important for synapse formation (Renner et al., 2009). One study has reported that cholesterol levels are low in children with autism suggesting that proteins involved in cholesterol synthesis could be candidate genes for ASD (Tierney et al., 2006). *Dhcr7* null mice die soon after birth. A complex heterozygous model with a single copy deletion of *Dhcr7* on one allele and a human missense mutation in the other allele, *Dhcr7^{ms/-}* results in increased ventricular size (Correa-Cerro et al., 2006).

Overall, these studies show genes that cause various neurodevelopmental disorders may also be relevant to specific changes in autism. It is important to note that these developmental disorders also have characteristics not associated with ASD. Therefore results from behavior studies should be critiqued carefully and should consider potential complications from phenotypes not associated with ASD. One thing we can learn from these models is neural

circuits and pathways potentially involved in ASD, which may be beneficial in identifying other potential targets for the study of autism. While not all developmental disorders with autistic-like behaviors may prove to be useful in studying ASD, there is a wealth of information to be gained from these models.

Synaptic and Signaling Genes Implicated in ASD

Altered brain growth is a common characteristic of ASD (Courchesne et al., 2004). Specifically, abnormal growth in the frontal lobe cerebellum and limbic structures are observed (Courchesne, 2004). These brain regions are important for development of social behaviors, communication, and motor coordination which are disrupted in patients with ASD (Sacco et al., 2007). Many proteins and pathways critical for neuronal growth and organization have been implicated in ASD including extracellular matrix proteins, neurotrophic factors, neurotransmitters, and transcription factors.

Alterations in synaptic function have also been proposed as a fundamental mechanism underlying ASD (Zoghbi, 2003). Additionally, as mentioned previously studies in mouse models of developmental disorders with ASD-like behaviors (FMRP, *Mecp2*, and *Ube3a*) exhibit synaptic defects. Not surprisingly, many of the candidate genes identified in the new genetic studies are synaptic proteins (Freitag, 2007). Many of these candidate genes have been made into transgenic animal models and are discussed below.

Neuroigin and Neurexin—Neuroigins and neurexins are trans-synaptic cell adhesion molecules involved in the formation and maintenance of excitatory and inhibitory synapses (Craig and Kang, 2007). Genetic studies have identified variations in the neuroigin genes *NLGN1*, *NLGN4X*, and *NLGN3* in a few cases of ASD (Betancur et al., 2009). Genetic studies involving individuals affected with ASD also identified variations in neurexins including a 2p16.3 deletion involving *NRXN1*, rare *NRXN1* specific deletions, sequence variants in *NRXN1*, and chromosomal abnormalities involving 2p16.3/*NRXN1* (Betancur et al., 2009). However, other studies show individuals with deletions and chromosomal abnormalities involving *NRXN1* in non-affected individuals (Betancur et al., 2009). Overall, there is evidence to support a role of neuroigins and neurexins in a small number of cases of ASD, and several transgenic models have been generated to explore the role of these proteins in ASD.

Two independent groups generated a transgenic mouse model that mimicked a point mutation in *NLGN3* found in human ASD patients, *NLGN* R451C. Tabuchi et al reported their mice show impaired social interactions in the three chamber social approach test, enhanced spatial learning in the Morris water maze, and enhanced inhibitory synaptic transmission with no effect on excitatory transmission (Tabuchi et al., 2007). The second group, Chadman et al, did not observe the same ASD-like phenotypes in their R451C line (Chadman et al., 2008). Specifically, using the same behavioral tests, they observed no difference in social approach or spatial memory in R451C mice compared to WT mice (Chadman et al., 2008). It is not clear why there is a discrepancy between the two lines. Possible reasons include the use of different inbred strains for the genetic background, or differences in methodology between the two studies.

In addition to point mutation knock-in mice, *NLGN* null mice for *NLGN* 1, 2, 3, and 4 have also been generated. *NLGN1* null mice show impaired spatial memory using the Morris water maze, and increased repetitive stereotyped grooming (Blundell et al., 2010). These mice also exhibit reduced NMDA/AMPA ratios in cortico-striatal synapses and impaired hippocampal LTP (Blundell et al., 2010). *NLGN3* and *NLGN4* null mice both exhibit deficits in ultrasonic vocalization and social behaviors (Jamain et al., 2008, Radyushkin et al., 2009). *NLGN4* null mice display deficient social approach and social memory in the

three chamber social approach test (Jamain et al., 2008). Additionally, male NLGN4 null mice showed decreased ultrasonic vocalization when exposed to a female mouse in estrous (Jamain et al., 2008). These deficits in ultrasonic vocalization are likened to deficits in communication found in human ASD cases. NLGN3 null mice also display decreased social memory in the three chamber social approach test and decreased ultrasonic vocalizations when exposed to a female mouse in estrous (Radyushkin et al., 2009). However, NLGN3 null mice did not show deficits in social interaction (Radyushkin et al., 2009). Finally, NLGN3 null mice exhibit olfactory deficits in the buried food finding test which may account for the lack of social memory. Interestingly, some ASD patients also exhibit olfactory deficits (Bennetto et al., 2007, Suzuki et al., 2003). These models suggest NLGN variations could be important in some cases of ASD.

There are three NRXN genes (1–3), and each gene encodes for a long (α) and short (β) isoforms which differ in their extracellular domains (Betancur et al., 2009). Abnormalities in α -NRXNs but not β -NRXNs are associated with ASD (Yan et al., 2008). Triple α -neurexin KO mice were not viable, double α -neurexin KO mice survived approximately one week, and even single α -neurexin KO mice experienced impaired survival (Missler et al., 2003). Double α -neurexin KO mice show α -neurexins are not critical for synapse formation but are important in synapse function (Dudanova et al., 2007). Altered functional coupling of Ca^{2+} channels to the presynaptic membrane and decreased Ca^{2+} -mediated neurotransmitter release is observed in brain slices from α -NRXN KO mice (Missler et al., 2003). This phenotype is rescued specifically by α -NRXN not β -NRXN (Zhang et al., 2005). A study using the single deletion NRXN1- α KO mice reveals altered excitatory transmission in the hippocampus (Etherton et al., 2009). Behavioral studies show decreased PPI, impaired nest building activity, and improved motor learning on the rotorod, which measures the ability of a mouse to maintain balance on a revolving rod over increasing speeds, but no obvious social defects (Etherton et al., 2009). Thus, NRXN also shows promise as a model for studying ASD.

22q13.3/SHANK3—SHANK (SH3 and multiple ankyrin repeat domains) is a family of scaffold proteins highly enriched in postsynaptic densities (Sheng and Hoogenraad, 2007). Shanks interact with many synaptic proteins including neuroligins, glutamate receptor complexes, and the cytoskeleton acting as a master scaffold in the PSD (Gerrow et al., 2006). Interestingly, over-expression of Shank1 in vitro results in dendritic spine enlargement (Sala et al., 2001). Additionally, expression of Shank3 is sufficient to induce dendritic spine formation in aspiny neurons (Roussignol et al., 2005). Alternatively, knockdown of Shank3 leads to decreased dendritic spine size in hippocampal neurons in vitro (Roussignol et al., 2005).

The smallest deletion capable of causing 22q13.3 deletion syndrome contains three genes including the *Shank3* gene and is characterized by global developmental delays, delayed or absent speech, and autistic behaviors (Cusmano-Ozog et al., 2007). Genetic studies of individuals with 22q13.3 syndrome indicate that *Shank3* is the critical gene in this disorder (Bonaglia et al., 2006). Specifically, individuals with balanced translocations involving *Shank3* or breakpoints within the *Shank3* gene display ASD characteristics (Bonaglia et al., 2006). Additionally, individuals with ringed chromosome 22 typically have deletion of the long arm and exhibit 22q13.3 deletion syndrome characteristics. However, individuals with a ringed chromosome 22 with no disruption of *Shank3* are phenotypically normal (Jeffries et al., 2005). Additional genetic studies identified variations within the *Shank3* gene including CNVs and SNPs that are associated with ASD (Sykes et al., 2009).

Currently, there are no published transgenic models of a Shank3 knockout. A Shank1 KO generated by Hung et al exhibits increased anxiety as assessed in the light dark emergence

test and the open field, impaired contextual fear memory, and impaired long-term memory retention using the radial arm test (Hung et al., 2008). Shank1, like Shank3, affects synaptic strength and dendritic spine maturation (Sala et al., 2001). Thus, a Shank3 mutant mouse could prove to be an interesting model for the study of ASD.

BDNF—BDNF is a neurotrophic factor important for axon guidance, dendritic growth during development, synaptic modulation, induction of LTP, and certain forms of learning and memory (Greenberg et al., 2009). *BDNF* has been identified as a candidate gene for ASD susceptibility (Pardo and Eberhart, 2007). Additionally, increased plasma levels of BDNF have been reported in children diagnosed with ASD (Connolly et al., 2006).

While BDNF-null mice die shortly after birth, BDNF heterozygous (BDNF^{+/-}) mice and conditional BDNF knockouts are viable and show altered behavioral phenotypes (Chan et al., 2006, Lyons et al., 1999). Forebrain specific deletion of BDNF resulted in males showing increased locomotor activity in the open field test, while females show increased depression-like behaviors as determined by the forced swim test and the sucrose preference test, a test of anhedonia (Monteggia et al., 2007). Targeted deletion of BDNF in either fetal or postnatal brains and BDNF^{+/-} mice exhibit hyperactivity, increased aggression in the resident intruder test, and altered serotonergic signaling (Chan et al., 2006, Daws et al., 2007, Lyons et al., 1999, Rios et al., 2001, Rios et al., 2006). Treatment of BDNF^{+/-} mice with fluoxetine, an SSRI, ameliorated the increased aggression (Lyons et al., 1999).

Interestingly, BDNF levels are increased in the brains of 5-HT_{2C} knockout mice (Hill et al., 2010). Reciprocally, 5-HT clearance and function are deficient in BDNF^{+/-} mice suggesting an association between BDNF levels and serotonin signaling (Daws et al., 2007, Lyons et al., 1999). Finally, behavioral deficits found in SERT null mice are exacerbated when crossed to BDNF^{+/-} mice suggesting the effects of SERT and BDNF may have cumulative detrimental effects (Murphy et al., 2003, Ren-Patterson et al., 2006, Ren-Patterson et al., 2005). Thus, BDNF may play a role in ASD and other psychiatric disorders, including Mood Disorders, by modulating serotonin signaling.

Another transgenic model, CADPS-2 (Ca²⁺-dependent activator protein for secretion 2), further implicates altered BDNF function as a potential contributor of ASD characteristics. CADPS-2 is a member of a family of proteins involved in exocytosis of dense-core vesicles, and is involved in the activity-dependent release of BDNF (Sadakata et al., 2004). *Cadps-2* knockout mice show impaired BDNF release (Sadakata et al., 2007). These mice also exhibit ASD-like behaviors including decreased social interactions when paired in a novel cage, maternal neglect, decreased interest in novel environments in the open field test, and home cage hyperactivity (Sadakata et al., 2007).

Serotonin Signaling—Serotonin (5-HT) signaling is involved in many neurodevelopmental processes including neurogenesis, cell migration, cell survival, synaptogenesis, and plasticity (Azmitia, 2001). Hyperserotonemia is one of the most consistent findings in patients with ASD (Hranilovic et al., 2008). Additionally, genetic studies in ASD patients identified genes involved in serotonin signaling, though some studies fail to identify these correlations (Huang and Santangelo, 2008). Finally, treatment with the SSRI fluoxetine mildly improves social behavior and decreases aggression and stereotyped behavior in children with autism (West et al., 2009). However, a new report shows no effect. Citalopram, an SSRI commonly prescribed to children with ASD, was found to be no more effective than placebo at reducing repetitive behaviors in children with ASD (King et al., 2009, Myers, 2010).

Several animals with targeted disruption of the serotonin transporter (5-HTT, SERT, SLC6A4) were generated to investigate the role of serotonin signaling. Bengel et al generated a 5-HTT null (5-HTT KO) mouse that resulted in insufficient clearing of 5-HT (Bengel et al., 1998). These 5-HTT KO mice have altered cortical thickness and cell density (Altamura et al., 2007). Interestingly, patients with variations in the 5-HTT gene have slower extracellular 5-HT clearance and show decreased gray matter volumes (Canli et al., 2005). 5-HTT null mice show greater anxiety in the elevated-plus maze, the light dark emergence test, and the open field (Carroll et al., 2007, Holmes et al., 2003). These mice also demonstrate hypoactivity, and decreased vertical activity (Kalueff et al., 2007). Additionally, these mice are more sensitive to stress than WT controls, and have altered hypothalamic-pituitary-adrenal (HPA) axis signaling (Jiang et al., 2009).

Veenstra-VanderWeele et al. identified a rare nonsynonymous variation in the serotonin transporter (Gly56Ala) in pedigrees carrying diagnoses of ASD and OCD. This Gly56Ala variant resulted in constitutively elevated SERT activity in human patients (Veenstra-Vanderweele et al., 2009). Generation of a transgenic mouse carrying the Gly56Ala variant showed normal gross morphology, though to date there has been no behavioral characterization (Veenstra-Vanderweele et al., 2009). Thus, the potential for this model is currently unknown.

PTEN—PTEN (Phosphatase and tensin homolog on chromosome ten) is a phosphatase for Phosphatidylinositol 3,4,5 triphosphate (PI3) that antagonizes signaling through the PI3K pathway and affects cellular proliferation, differentiation, and migration (Stiles, 2009). PTEN abnormalities are usually associated with syndromes including Cowden's syndrome (a disorder characterized by the development of hamartomas) and TSC, and often exhibit features such as macrocephaly, seizures, and mental retardation (Pilarski and Eng, 2004). Genetic studies show some ASD patients have variations in the *PTEN* gene (Buxbaum et al., 2007). Additionally, many individuals affected with Cowden's syndrome and TSC are also diagnosed with ASD (Goffin et al., 2001). *PTEN* variations have also been identified in some ASD patients with macrocephaly (Butler et al., 2005).

Conditional deletion of PTEN in a select population of mature neurons in the cortex and hippocampus using neuron-specific enolase (Nse)-cre results in decreased social approach when paired in a neutral cage or in the three chamber social approach test, increased activity in the open field, and impaired PPI (Kwon et al., 2006, Ogawa et al., 2007). Additionally, these mice show progressive macrocephaly. This correlates well with abnormalities observed in Cowden syndrome and may model the increased head circumference seen in autistic children (Hazlett et al., 2005). In addition to the macrocephaly and behavioral abnormalities observed in the Nse-Cre PTEN mice, there are also changes in neuronal morphology observed including loss of polarity and neuronal hypertrophy (Kwon et al., 2006, Ogawa et al., 2007). mTORC1 (Mammalian target of rapamycin complex 1) is a downstream target of PTEN (Stiles, 2009). Interestingly, a recent study shows rapamycin, a specific inhibitor of mTORC1, can reverse many of the behavioral abnormalities seen in the Nse-Cre PTEN mice (Zhou et al., 2009). These studies suggest downstream targets of PTEN may be useful therapeutic targets for treating ASD, particularly in cases associated with macrocephaly.

Oxytocin/ Vasopressin—Oxytocin (OT) is a hypothalamic neuropeptide with receptors located in various brain regions associated with anxiety and social behavior including the olfactory bulb, piriform cortex, amygdala, and lateral septum (Landgraf and Neumann, 2004). In particular, OT release can facilitate decreases in anxiety and stress responses (Parker et al., 2005). Genetic studies have identified *OT* as a candidate gene of ASD

(Gregory et al., 2009). Additionally, treatment with OT inhalation increased social interactions in individuals with ASD (Andari et al., 2010).

Three different OT null mice were generated to study the role of endogenous OT (Gross et al., 1998, Nishimori et al., 1996, Young et al., 1996). The line generated by Young and colleagues showed reduced maternal retrieval and reduced aggression when OT null mice were paired in a neutral cage (DeVries et al., 1997, Pedersen et al., 2006). Odorant detection defects were observed in female knockouts from the line generated by Gross and colleagues (Kavaliers et al., 2003). Social memory as assessed in the resident intruder test was deficient in male knockout mice from the lines generated by Nishimori and colleagues with no deficits in normal social interactions (Ferguson et al., 2000, Winslow and Insel, 2002). Additional studies found deletion of either OT or the OT receptor (OTR KO) decreased social recognition, social memory, and ultrasonic vocalizations of male pups subjected to social isolation (Lee et al., 2008, Takayanagi et al., 2005). No difference in social approach in the OT KO was found using the three chamber social approach test (Crawley et al., 2007). There were some differences in social recognition between the total OTR and the forebrain specific OTR knockout (OTR^{FB/FB}) (Lee et al., 2008). A follow-up study found male OTR^{FB/FB} mice can differentiate between inter-strain females but not intra-strain females (Macbeth et al., 2009). These differences between the total and conditional OTR knockouts could be due to differences in temporal or spatial expression. Further studies to dissect the specific role of OT in the various social paradigms will be helpful in determining how OT affects social behavior.

Arginine Vasopressin (AVP), another hypothalamic neuropeptide, may also be altered in ASD (Yirmiya et al., 2006). Normal AVP function is implicated in typical male social behaviors in animals including aggression, scent marking, courtship, and pair-bonding (Carter et al., 2008). Two of the AVP receptors are expressed in the CNS, V1aR and V1bR. V1aR is located throughout the brain while V1bR is most highly expressed in the amygdala (de Vries and Miller, 1998). V1aR knockout mice show profound deficits in social recognition using ovariectomized females introduced to the home cage, and decreased anxiety in the elevated plus maze and the light dark emergence test (Bielsky et al., 2004). Social discrimination is rescued with viral reintroduction of the V1aR specifically in the lateral septum (Bielsky et al., 2005). V1bR knockout mice show reduced social aggression, reduced social motivation, and impaired social memory (Caldwell et al., 2008). V1bR KO mice also exhibit decreased ultrasonic vocalizations in social environments both as pups and adults (Scattoni et al., 2008).

Overall, OT and AVP are thought to be important for social behavior. Transgenic mouse models of OT and AVP both exhibit ASD-like behaviors. Thus, models of OT and AVP show great promise for understanding mechanisms involved in social recognition and interactions, behaviors that are severely affected in ASD.

Other ASD Models

Reelin (RELN) is an extracellular matrix protein involved in cell guidance, dendrite formation, and synaptogenesis (Tissir and Goffinet, 2003). Genetic studies show a CGG trinucleotide repeat in the 5'UTR of the *Reln* gene is associated with cases of ASD (Zhang et al., 2002). However, a separate study failed to identify an association (Krebs et al., 2002). Reeler mice have a spontaneous deletion that resulted in a loss of the majority of the *Reln* gene (Goffinet, 1984). Homozygous mice completely lack reelin, have severe structural alterations in several brain regions including the cortex, cerebellum and hippocampus, have severe ataxia or altered gait, and deficits in ultrasonic vocalizations have been recorded selectively in socially isolated male pups (Goffinet, 1984, Ognibene et al., 2007). Alternatively, heterozygous reeler mice show loss of Purkinje cells in the cerebellum and

subtle neuro-anatomical abnormalities (Tueting et al., 1999). Studies with heterozygous reeler mice show decreased PPI, deficits in odor discrimination, decreased anxiety in the elevated plus maze, and impaired conditioned fear in the active avoidance test (Marrone et al., 2006, Tueting et al., 1999), though some studies do not support these findings (Podhorna and Didriksen, 2004, Salinger et al., 2003).

Dishevelled-1 (Dvl-1) is a protein involved in the Wingless-Int (WNT) signaling pathway. WNT signaling is involved in cell migration, cell survival, dendritic morphogenesis, and synapse formation. *WNT2* has been identified as a candidate gene for ASD susceptibility (Wassink et al., 2001). Targeted disruption of *Dvl1* leads to altered home cage behavior, social interaction deficits including subordinate behavior in social dominance paradigms, and changes in synapse formation (Long et al., 2004). However, these mice demonstrate normal ultrasonic vocalization, spatial learning, and hippocampal synaptic plasticity (Long et al., 2004). (See also Mood Disorders)

Engrailed 2 (EN2) is a transcription factor important in neurodevelopment and is critical in the formation of specific serotonergic and noradrenergic nuclei in the mid- and hindbrain (Simon et al., 2004). EN2 is also important for the survival of specific subpopulations of dopaminergic neurons (Sgado et al., 2006). Genetic studies show SNPs of *EN2* are associated with ASD (Benayed et al., 2005), though some studies fail to confirm this (Zhong et al., 2003). EN2 knockout and missense mutant mice show a decrease in the number of purkinje neurons (Baader et al., 1998). Additionally, EN2 knockout mice show social deficits as juveniles in reduced social play and as adults in decreased aggression when paired in a neutral environment (Cheh et al., 2006). EN2 knockout mice show reduced spatial learning in the Morris water maze, and are hyperactive with impaired motor coordination as observed in the open field test (Cheh et al., 2006). A better understanding of the genes regulated by EN2 and how these genes may be involved in pathways important for the development of social behaviors may be useful in the study of ASD.

III. Mood Disorders

Bipolar disorder (BD) is a mood disorder characterized by recurrent episodes of mania (type 1) or hypomania (type 2) and episodes of depression in a single individual (APA, 2000). Other mood disorders include major depressive disorder (MDD), cyclothymia, and BD not otherwise specified. The risk of developing BD in a lifetime is approximately 1–4% (Merikangas et al., 2007). BD is highly heritable with many cases having a clear genetic basis (Barnett and Smoller, 2009). Twin studies show the concordance in MZ twins is 38.5–43% while DZ twins is only 4.5–5.6% (Kieseppa et al., 2004). Additionally, linkage and association studies have identified many chromosomal regions and candidate genes for BD (For a detailed review of BD genetics see (Barnett and Smoller, 2009))

The development of mouse models of BD with the critical feature of cycling between mania and depression is currently not established. However, there has been success in generating unipolar models of mania and depression. The discovery of genes directly linked to BD and a better understanding of the neurological basis of cycling between mania and depression will facilitate the development of more effective treatment. Several pharmacological, nutritional, and environmental models are used in the study of Mood Disorders, for a review of these models see Kato et al (Kato et al., 2007). Here we will focus on transgenic models of mood disorders.

Clock Mutant

Altered circadian processes including sleep, activity, and hormonal secretions are common characteristics found in mood disorder patients (Wood et al., 2009). Disruption of sleep/

wake cycles can trigger manic phases, while stabilization of sleep/wake cycles is often essential for mood stabilization (Boivin, 2000). Additionally, depression symptoms are more prevalent in winter months and regions that receive significantly less daylight (Saeed and Bruce, 1998). Association studies identified several circadian genes as susceptibility genes for BD including *CLOCK*, *BMAL1* (aryl hydrocarbon receptor nuclear translocator-like), *PERIOD3*, *ARNTL* (aryl hydrocarbon receptor nuclear translocator-like), *DBP* (D site of albumin promoter (albumin D-box) binding protein), and *TIMELESS* (Mansour et al., 2006).

CLOCK is a transcription factor that forms a complex with *BMAL1* and induces the expression of several genes that are involved in regulating circadian rhythm through a time-delayed transcription-translation feedback loop (King and Takahashi, 2000). Disruption of the *CLOCK* gene in mice led to hyperactivity in the open field, disrupted circadian rhythms and decreased sleep determined by the running wheel test and monitoring of brain wave patterns, decreased anxiety in the open field and elevated plus maze, increased reward for sucrose and cocaine using the reward/aversion test, and reduced depression-like behavior in the forced swim test and the learned helplessness test (King et al., 1997, McClung et al., 2005, Naylor et al., 2000, Roybal et al., 2007, Easton et al., 2003). Importantly, clinically relevant doses of lithium improved the manic-like phenotype in the *CLOCK* mice (Gelenberg et al., 1989, Roybal et al., 2007). Additionally, reintroduction of WT *CLOCK* in the ventral tegmental area (VTA) returned locomotor activity and anxiety levels to near wild type control levels (Roybal et al., 2007).

The clock gene D-box binding protein (*Dbp*) is also a candidate gene for BD (Niculescu et al., 2000). *Dbp* null mice show lower locomotor activity in the open field and blunted response to stimulants compared to control animals as seen by atypical reduction in stereotypy behavior with administration of methamphetamines (Le-Niculescu et al., 2008). Interestingly, upon infliction of chronic stress, these mice demonstrate a change in phenotype. Specifically, sleep deprivation leads to increased activity levels, and exposure to stress leads to increased alcohol intake (Le-Niculescu et al., 2008).

POLG

Defects in mitochondrial DNA (mtDNA) and calcium homeostasis have been found in patients with BD (Stork and Renshaw, 2005). Additionally, variations in mtDNA have been associated with BD (Kato, 2002), though one study did not replicate these findings (Munakata et al., 2004).

mtDNA polymerase (POLG) mutant mice were generated to study chronic progressive external ophthalmoplegia (CPEO), a mitochondrial disorder that often has comorbidity with mood disorders (Kasahara et al., 2006). Transgenic mice with forebrain specific expression of mutant POLG exhibit several behavioral characteristics of BD including altered circadian rhythm and reduced overall wheel running activity in the running wheel test (Kasahara et al., 2006). Additionally, female but not male mice show periodic activity changes in relation to estrous (Kasahara et al., 2006). Treatment with the tricyclic antidepressant, amitriptyline, which can cause a manic-switch in BD patients also led to a manic switch-like behavioral change in the POLG mice (Kasahara et al., 2006). Specifically, administration of amitriptyline resulted in increased wheel running during the light phase and increased locomotor activity selectively in POLG mice. Importantly, lithium improves the periodic activity changes associated with the estrous cycle and circadian rhythm disruptions observed in these mice, but not the overall wheel running activity. The authors suggest the responses to tricyclic antidepressants and lithium indicate the POLG mice may be a good model for studying BD.

Glucocorticoid Receptor

Clinical studies show a majority of patients with depression have hyperactivity of the hypothalamic-pituitary-adrenal (HPA) system and elevated plasma cortisol levels (Holsboer, 2000). The glucocorticoid receptor (GR) modulates many neuronal functions including stress responsiveness and cognitive function (de Kloet et al., 1999). Additionally, BAG-1(BCL2-associated athanogene), a GR co-chaperone, was found to be a target of mood stabilizers further implicating this pathway as important in BD (Zhou et al., 2005). Finally, genetic association studies have found gene variations in *GR* to be associated with Major Depression (MD) (van West et al., 2006).

Several animal models with altered GR function have been generated including a point mutation to prevent GR dimerization (GRdim), a brain specific knockout of GR (GRnescre), and a GR missense model with reduced GR expression in the brain and some peripheral tissues (Pepin et al., 1992, Reichardt et al., 1998, Tronche et al., 1999). The GRdim model did not show any depressive, manic, or anxiety-like differences (Oitzl et al., 2001). GRnescre mice show deficient acquisition of stress-coping as determined by the forced swim test, and decreased anxiety in the elevated plus maze and light dark emergence test (Tronche et al., 1999). Missense GR mice show decreased anxiety in the elevated plus maze, but increased anxiety in the open field (Montkowski et al., 1995, Strohle et al., 1998). The difference in anxiety phenotypes is suggested to be related to the stress-inducing environment of the open field (Strohle et al., 1998).

Generation of a transgenic mouse model with forebrain specific over-expression of GR (GRov) by Wei et al resulted in an animal model with increased sensitivity to both positive and negative stimulation. Specifically, these mice exhibit increased depression-like behaviors in the forced swim test, anxiety-like behaviors in the elevated plus maze, high sensitivity to anti-depressants, and hypersensitivity to cocaine administration (Wei et al., 2004).

Ridder et al evaluated a pair of GR mutant mice, one with a 50% reduction in GR expression (GR+/-), and one with over-expression of GR. Under basal conditions the GR+/- mice show normal levels of cortisol and normal behaviors (Ridder et al., 2005). Stress inducing protocols generated higher levels of cortisol as well as depression-like behaviors in the forced swim test and learned helplessness test in GR+/- mice compared to WT. Alternatively, the GR over-expression mice show greater resistance to depression-like behaviors compared to WT controls. The GR over-expression mice however, do not exhibit an anxiety-like phenotype in the elevated zero maze and the light dark emergence test as observed in the GRov mice that specifically over-express GR in the forebrain (Ridder et al., 2005, Wei et al., 2004). The authors suggest the use of different promoters in the two lines could explain the differences in behavioral characteristics between the two lines.

Other Mood Disorder Models

GSK-3 β (Glycogen synthase kinase-3 β) is a serine/threonine kinase involved in many different cellular processes (Doble and Woodgett, 2003). One role of GSK-3 β is regulation of circadian rhythm, which as mentioned above is disrupted in BD (Kaladchibachi et al., 2007). Interestingly, GSK3 β activity is inhibited by the WNT signaling cascade through Dvl1 (a model described in the ASD section) (Chen et al., 2001b). Dvl1 KO mice show deficits in sensory motor gating, which is impaired in individuals with BD (Lijam et al., 1997). Importantly, GSK-3 β is inhibited by both lithium and valproic acid, which are both used to treat BD (Chen et al., 1999, Klein and Melton, 1996). However, an association study failed to identify *GSK-3 β* as a genetic risk factor for BD (Nishiguchi et al., 2006). Transgenic mice over-expressing GSK-3 β have increased locomotor activity and decreased

habituation, hypophagia, increased acoustic startle response, and increased mobility in the forced swim test (Prickaerts et al., 2006). Thus it is suggested this could be a model for hyperactivity as seen in mania.

Wolfram syndrome (WFS) is an autosomal recessive disorder that is defined by the occurrence of diabetes mellitus and bilateral optic atrophy, and is often accompanied by depression (Swift et al., 1990). Additionally, the *WFS1* gene was mapped to a region on chromosome 4p16.1, a linkage locus of BD (Polymeropoulos et al., 1994). Interestingly, variations in the *WFS1* gene have been found in patients with BD, MD, SZ, suicide victims, as well as several other psychiatric disorders without comorbidity of Wolfram syndrome (Swift and Swift, 2000). Initial characterization of a *WFS1* knockout (*WFS1* KO) found these mice show increased endoplasmic reticulum (ER) stress and increased vulnerability to cell death (Yamada et al., 2006), which is alleviated with administration of valproate, a drug used in treatment of BD (Kakiuchi et al., 2009). More recent studies with *WFS1* KO mice show normal circadian rhythm in the running wheel test (Kato et al., 2008). However these mice did show decreased social interaction when paired in a neutral cage, increased behavioral despair in the active avoidance test and latency to escape the Morris water maze, and decreased behavioral despair in the forced swim test (Kato et al., 2008, Raud et al., 2009).

PKCI/HINT1 (Protein Kinase C interacting protein) is a member of the histidine triad (HIT) protein family (Klein et al., 1998). *PKCI* was identified as a candidate gene for BD and SZ through microarray analysis of human postmortem brains diagnosed with BD or SZ respectively (Elashoff et al., 2007, Vawter et al., 2002). An expression analysis study found that *PKCI* expression was primarily found in parvalbumin positive interneurons in the cortex and limbic regions, which are regions implicated in mood disorders (Liu et al., 2008). *PKCI/HINT1* null mice show normal locomotor activity in the open field, and exhibit greater sensitivity to amphetamine than WT controls (Barbier et al., 2007). *PKCI/HINT1* KO mice exhibit decreased immobility in the tail suspension test, and this is partially alleviated with administration of valproate. Additionally, *PKCI/HINT1* KO mice exhibit less immobility in the forced swim test, increased HPA axis basal activity, and increased time spent in the light compartment during the light dark emergence test, which is consistent with mania-like behavior (Barbier and Wang, 2009).

IV. Obsessive-Compulsive Spectrum Disorders (OCSD)

Obsessive Compulsive Disorder (OCD) is a disorder characterized by persistent intrusive thoughts (obsessions) and the expression of ritualistic repetitive behaviors (compulsions) which are often performed in an attempt to alleviate intense anxiety caused by the obsession (Leckman et al., 2007). Common obsessions include fear of contamination and fear of harming oneself or others (Lochner et al., 2008). Common compulsions include excessive hand washing or grooming, counting, checking, telling or confessing, repeating, and hoarding (Lochner et al., 2008). OCD affects 1–3% of the world's population, with approximately equal ratios of affected adult males to females (Rasmussen and Eisen, 1994). In children, however, there is a 2–3:1 ratio of affected males to females (Kalra and Swedo, 2009). Current treatment of OCD consists of pharmacotherapy, cognitive-behavioral therapy (CBT), or both. However, treatment at best only partially relieves OCD behaviors. Thus a better understanding of OCD is necessary to improve the treatment options available.

Other disorders classified as OCSDs include Tourette Syndrome (TS), Trichotillomania (TTM) or compulsive hair pulling, Body Dysmorphic Disorder (BDD), and Dermatillomania or Compulsive Skin Pulling (CSP) (Phillips, 2002). Additionally, compulsive hoarding and eating disorders including anorexia are proposed OCSDs (Bellodi

et al., 2001, Samuels et al., 2007). In considering the relevant disorders, OCSDs may affect as much as 10% of the general population (Dell'Osso et al., 2007).

Several genetic studies including twin studies, family studies, and association and linkage studies show that OCD has a strong genetic component (Nicolini et al., 2009). Twin studies show monozygotic twins have a greater concordance rate for OCD (80–87%) than dizygotic twins (47–50%) (Carey and Gottesman, 1981). A family study by Pauls et al. showed individuals with first-degree relatives diagnosed with OCD have a greater incidence of OCD (7.9–10%) than relatives of control individuals (2.0%) (Pauls et al., 1995). These findings were confirmed by additional family studies analyzed by other groups (Grabe et al., 2006, Nestadt et al., 2000). Linkage studies of families with at least two affected family members identified a strong association with 9p24, 10p15, 11p15, and 14 (Nicolini et al., 2009). Large scale analysis studies will be important for confirming these linkage sites. In particular, an ongoing collaborative genetic study by six universities will collect information from hundreds of families with individuals diagnosed with OCD (Samuels et al., 2006). This consortium of data and samples will be available to researchers and is sponsored by the NIMH. To date, over 60 candidate genes for association with OCD have been identified. These genes implicate the involvement of the serotonergic, glutamatergic, and dopaminergic systems in OCD (Nicolini et al., 2009). One particular circuit gaining support as a major factor in OCD is the cortico-striatal-thalamo-cortical (CSTC) circuit (Ting and Feng, 2008).

D1CT transgenic mouse

The D1CT transgenic mouse model was generated by expressing an intracellular form of cholera toxin (CT), a neuro-potentiating enzyme, under the control of the D1 promoter (Campbell et al., 1999). These transgenic mice have chronic potentiation of D1 positive subsets of neurons in the brain. Expression in the D1CT-7 line was predominantly restricted to neurons within the intercalated nucleus of the amygdala and cortical area that project to the striatum and orbitofrontal cortex.

Behavioral studies in D1CT mice show several abnormalities resembling OCD-like behaviors. Specifically, these mice demonstrated repetitive non-aggressive biting of siblings during grooming, repetitive climbing/leaping, and extended bouts of repetition during normal behavior (Campbell et al., 1999). D1CT-7 mice also exhibit increased levels of anxiety as observed in open field and light dark emergence tests when compared to WT littermates (McGrath et al., 1999). Additionally, D1CT-7 mice exhibit TS-like behaviors including juvenile-onset tics defined as isolated head and/or body jerks or shakes (Nordstrom and Burton, 2002). Importantly, administration of clonidine to D1CT-7 mice reduced tics observed in these mice similar to results found in human TS patients (Cohen et al., 1979). Unfortunately, the effect of SSRIs in these mutant mice has yet to be evaluated.

5-HT_{2C} Receptor

The 5-HT_{2C} serotonin receptor (5-HT_{2C}-R) subtype is broadly expressed in the brain and mediates much of the serotonin signaling in the brain (Goddard et al., 2008). Additionally, the 5-HT_{2C}-R is thought to mediate the actions of serotonin underlying the therapeutic benefits of SSRI treatment in OCD (Goddard et al., 2008). The initial characterization of 5-HT_{2C}-R null mice found that these mice experience mid-life obesity due to hyperphagia, are prone to death from spontaneous seizures, and exhibit altered sleep homeostasis (Tecott et al., 1995, Chou-Green et al., 2003b). Later studies observed compulsive behaviors in the 5-HT_{2C}-R null mice more characteristic of some OCD-like behaviors (Chou-Green et al., 2003a). Specifically, the 5-HT_{2C}-R null mice show increased chewing of non-nutritive clay and “neat” chewing patterns in plastic screens suggesting compulsive behavior (Chou-Green et al., 2003a). This study also observed increased head dipping in knockout mice compared

to wild type mice (Chou-Green et al., 2003a). The authors suggest the clay and screen chewing and increased head dipping are comparable to compulsive behaviors observed in OCD patients. Finally, 5-HT_{2C}-R null mice show less anxiety symptoms than WT mice (Heisler et al., 2007). These mice show increased time and activity in the open quadrant of the elevated plus maze, increased time spent in the center of the open field, increased exploration of novel objects, and increased time in a mirrored chamber (Heisler et al., 2007). These mice also show decreased corticotropin hormone release from the extended amygdala in response to anxiety stimuli compared to control mice.

Recently, Kimura et al. generated a transgenic mouse with overexpression of 5-HT_{2C}-R in the forebrain (C2CR) driven by the CamKII α promoter (Kimura et al., 2009). These mice showed elevated anxiety as measured by the elevated plus maze and hypo-locomotion as measured in the open field. This mouse line does not exhibit weight or eating issues as the hypothalamus is not affected in this mouse. Thus, 5-HT_{2C}-R mice may be useful in exploring neuronal circuitry mediating anxiety, which is commonly increased in OCD patients.

SAPAP3

SAPAP3 (SP90/PSD95-associated protein 3) belongs to a family of four homologous genes encoding proteins that are widely yet differentially expressed in the nervous system (Welch et al., 2004). The SAPAP family of proteins are scaffold proteins that localize to excitatory synapses (Takeuchi et al., 1997). Recent human genetic studies have identified multiple rare *SAPAP3* missense variants in TTM and OCD patients, which suggest an association of OCD/TTM with *SAPAP3* disruption (Zuchner et al., 2009).

Deletion of *SAPAP3* (*SAPAP3* KO) led to compulsive self-grooming to the point of hair loss and the development of skin lesions (Welch et al., 2007). Importantly, there was no evidence for skin abnormalities or sensory innervation defects in these mice suggesting that the increased grooming is a result of compulsive behavior not skin aggravation. Additionally, the *SAPAP3* KO mice showed increased anxiety in the open field, the light dark emergence test, and the elevated zero maze (Welch et al., 2007).

SAPAP3 is the only family member that is highly expressed in the striatum (Welch et al., 2004). Therefore, *SAPAP3* KO mice were evaluated for defects in cortico-striatal synaptic transmission by electrophysiology. Field excitatory postsynaptic currents (fEPSCs) were decreased in *SAPAP3* KO mice (Welch et al., 2007). Importantly, rescue of both the cortico-striatal dysfunction and compulsive grooming was achieved through viral reintroduction of WT *SAPAP3* specifically into the striatum. These results suggest that synaptic dysfunction in the striatum might be a central mechanism for the expression of compulsive grooming. Interestingly, DAT KD mice also show disruption in cortico-striatal synapses, and the *DICT* mice also are suggested to have cortico-striatal defects though it has not been directly tested. If other models of OCD, specifically models with compulsive/repetitive behaviors, are found to have similar corticostriatal defects, this could establish a link between a common circuitry defect with a specific OCD-like behavior.

Administration of 5mg/kg fluoxetine, an SSRI, for six days was able to partially rescue the compulsive grooming behavior in *SAPAP3* KO mice. Fluoxetine treatment also seems to alleviate anxiety levels as observed through decreased latency in the light dark emergence test. While a single dose of fluoxetine was not sufficient to alleviate the overgrooming, the treatment dose and timecourse is lower and shorter than typical treatment with fluoxetine in OCD patients (Ackerman et al., 1998, Jenike, 2004). Overall, the *SAPAP3* KO mouse is a promising model for understanding the circuitry involved in compulsive/repetitive behavior.

Slitrk5

Slitrk (SLIT and NTRK-like family, member) proteins (Slitrk1–6) are single-pass transmembrane proteins that control neurite outgrowth (Aruga and Mikoshiba, 2003). Variations in *Slitrk1* (discussed below) have been identified in patients with TS and TTM (Abelson et al., 2005, Zuchner et al., 2006). Currently, the potential involvement of other Slitrk family members in psychiatric disorders is not well characterized. To fully characterize the expression pattern and evaluate the functional role of Slitrk5, Shmelkov et al replaced the Slitrk5 gene with a lacZ reporter gene to generate a Slitrk5 knockout (Slitrk5 KO). Expression analysis showed a wide expression pattern including the cortex, hippocampus, and striatum (Shmelkov et al., 2010).

Behavioral observations of the Slitrk5 KO showed these mice have increased grooming compared to WT littermates which results in severe skin lesions. Chronic treatment with the SSRI fluoxetine alleviated the overgrooming behavior in Slitrk5 KO mice but had no effect on WT mice. Additionally, Slitrk5 KO mice showed increased anxiety-like behaviors as determined by the elevated plus maze, the open field, and compulsive-like behavior in the marble burying test (Shmelkov et al., 2010).

Slitrk5 is expressed in many brain regions, however FosB expression, a marker of neuronal activity, was found to be elevated exclusively in the orbitofrontal cortex of Slitrk5 KO mice (Shmelkov et al., 2010). Interestingly, imaging studies in patients with OCD also showed increased activity in the orbitofrontal cortex (Menziez et al., 2008). Slitrk5 KO mice also had decreased volume and dendritic arbor complexity selectively in the striatum (Shmelkov et al., 2010). As mentioned previously, defects in cortico-striatal circuitry have been implicated in OCD, therefore Slitrk5 KO mice were evaluated for defects in cortico-striatal signaling by electrophysiology. Slitrk5 KO mice had decreased fEPSCs recordings, indicating these mice have defects in cortico-striatal signaling. Biochemical studies also showed total and synaptic glutamate receptor subunits were decreased in the striatum. Overall, the Slitrk5 KO mice exhibit OCD-like behaviors of compulsive grooming and anxiety, and have selective defects in cortico-striatal signaling. Thus the Slitrk5 KO is a promising model for the study of cortico-striatal defects in OCD.

Other OCD models

Hoxb8 is a member of the mammalian HOX (homeobox-containing) family of transcription factors best characterized for their role in early development (Capecchi, 1997). Hoxb8 is broadly expressed in the adult brain including the basal ganglia, hippocampus, cortex, and cerebellum (Greer and Capecchi, 2002). To address the role of Hoxb8, Greer and Capecchi generated a transgenic mouse line that was homozygous for a loss-of-function allele of Hoxb8. These mice exhibited excessive self and cage mate grooming that resulted in hair removal and skin lesions both on themselves and wild type cage mates (Greer and Capecchi, 2002). Importantly, these mice were found to have no underlying skin abnormalities and the lesions developed with 100% penetrance (Greer and Capecchi, 2002). Recently Chen et al. found that in the brain, Hoxb8 exclusively labels a sub-population of microglia. This sub-population seems to have a bone marrow origin. They also observed a reduction in the total number of microglia in Hoxb8 mutant mice compared to WT mice (Chen et al., 2010). Importantly, their data shows that transplantation of wild-type bone marrow rescues the excessive grooming in the Hoxb8 mutant mice (Chen et al., 2010). Additionally, deletion of Hoxb8 selectively in hematopoietic cells using a conditional knockout line was sufficient to induce pathological grooming in mice (Chen et al., 2010). The authors suggest three potential mechanisms for the role of microglia in modulating neuronal activity. First, the release of cytokines could work in parallel with neurotransmitters to stimulate or inhibit neuronal activity (Chen et al., 2010). Microglia have also been shown to function in

regulated neuronal cell death during embryogenesis (Frade and Barde, 1998, Marin-Teva et al., 2004). Therefore, another potential mechanism is through possible loss of appropriate cell death leading to altered neuronal connectivity resulting in aberrant behavior (Chen et al., 2010). Finally, microglia processes are very dynamic and have been shown to contact synapses in an activity dependent manner (Wake et al., 2009). Thus, a third potential mechanism is through altered microglia modulation of neuronal networks leading to altered behavior. Importantly, the *Hoxb8* subpopulation of microglia are most abundant in the cortex including the orbital regions, and basal ganglia (Chen et al., 2010). This is intriguing as the orbitofrontal cortex and basal ganglia are two brain regions implicated in human OCD (Graybiel and Rauch, 2000, Huey et al., 2008). While these potential mechanisms have yet to be explored, they propose a very interesting role for the immune system in modulating behavior.

The DAT KD mouse, previously described above as a model for ADHD and mania, also exhibits OCD-like behaviors. The hyper-dopaminergic DAT KD mice exhibit sequential super-stereotypy, and showed greater resistance to disruption of this pattern than control animals (Berridge et al., 2005). Interestingly, the basal ganglia is thought to organize sequential patterns of movement and thought, including grooming patterns (Lieberman, 2001, Marsden, 1984). The importance of DAT in regulating dopaminergic neurotransmission in the basal ganglia suggests that DAT disruption might be directly associated with OCD.

Aromatase cytochrome P450 (P450arom), the product of the *cyp19* gene, catalyzes the final step of biosynthesis of estrogen from androgens. Estrogen plays an important role in the development of both males and females. To study the role of aromatase activity in mice, targeted disruption of the *cyp19* gene led to the generation of aromatase knockout (Arko) mice which are estrogen deficient (Fisher et al., 1998). The absence of estrogen in male Arko mice, but not female Arko mice, resulted in compulsive behaviors including excessive grooming, barbering, increased wheel running, and reduced PPI up to 18 months of age (Hill et al., 2007, van den Buuse et al., 2003). Male Arko mice also exhibit a decrease in the expression of catechol-O-methyltransferase (COMT), a major enzyme regulating dopamine degradation, in the hypothalamus with no difference in the frontal cortex (Hill et al., 2007). Interestingly, low COMT activity has been suggested as a risk factor in human OCD, specifically in males (Karayiorgou et al., 1999, Pooley et al., 2007, Schindler et al., 2000). Additionally, some evidence does exist for involvement of the hypothalamus in grooming and wheel running behaviors (Rhodes et al., 2003). Thus, male Arko mice may be a good model to evaluate the role of the hypothalamus in OCD-like behaviors.

Expression of *Slitrk1*, another member of the *Slitrk* family of proteins, is abundant in the olfactory bulb, frontal cortex, hippocampus, and amygdala (Katayama et al., 2010). Variations in *Slitrk1* have been identified in patients with TS and TTM (Abelson et al., 2005, Zuchner et al., 2006). *Slitrk1* KO mice show decreased locomotor activity in light cycles, anxiety-like behaviors in the elevated plus maze and the light dark emergence test, and depression like behaviors in the forced swim test (Katayama et al., 2010). Neurochemical analysis of *Slitrk1* KO mice show increased NE levels in the mPFC and NAc, while choline (CH) and acetylcholine (ACh) levels were decreased in the striatum (Katayama et al., 2010). Both NE and CH/ACh signaling are involved in mediating fear and anxiety (Brioni et al., 1993, Hu et al., 2007). Interestingly, clonidine, an alpha2-adrenergic agonist known to be effective in treating some TS patients (Robertson, 2006), was effective in treating the anxiety in *Slitrk1* KO mice but had no effect on locomotor activity (Katayama et al., 2010).

V. Schizophrenia

Schizophrenia (SZ) is a neuropsychiatric disorder that affects approximately 1% of the world's population (Wu et al., 2006). SZ is characterized by the presence of three categories of symptoms: positive symptoms (hallucinations, delusions, and psychosis), negative symptoms (anhedonia, social defects, impaired motivation), and cognitive deficits (impaired working memory, attention, and execution) (APA, 2000). Although onset of SZ typically occurs in early adulthood (AOS), rare cases of childhood onset SZ (COS) occur in children as early as six years old (Rapoport et al., 2005). Studies show there is a significant genetic component for SZ (O'Donovan et al., 2009). Additionally, several pathways have been implicated in SZ including glutamatergic and GABA-ergic transmission (O'Tuathaigh et al., 2007).

Many SZ susceptibility genes are also associated with other childhood onset psychiatric disorders. Therefore many transgenic mouse models of SZ susceptibility genes were presented in previous sections of this review. For example, *PKCI/HINT1* is associated with both SZ and Mood Disorders. Additionally, *reln*, *BDNF*, and *neuregulin 1* are associated with SZ and ASD. Because SZ is mostly an adult onset psychiatric disorder, we have limited our presentation of SZ models to those genes associated with other disorders discussed in this review, and in this section the most prominently characterized SZ transgenic models to date.

22q11 deletion syndrome

22q11 deletion is a chromosomal abnormality associated with mental disorders. The smallest known deletion affects a minimum of 30 genes, and several of these genes have been associated with SZ and BD (Lindsay et al., 1995). In fact, patients with the 22q11 deletion exhibit both SZ and BD symptoms (Paylor and Lindsay, 2006). Several models of 22q11 exist including models that mimic the deletion seen in human patients, models with smaller deletion regions, and models with targeted deletion of specific genes contained within the deleted region (Jerome and Papaioannou, 2001, Kimber et al., 1999, Lindsay et al., 1999, Lindsay et al., 2001, Puech et al., 2000, Long et al., 2006).

One model, the *Df(16)A+/-* transgenic mouse, deletes a subset of genes affected in 22q11 syndrome (Mukai et al., 2008, Stark et al., 2008). Studies involving the *Df(16)A+/-* mouse model show impaired PPI, decreased working memory in the T maze, impaired response to contextual fear-conditioning, hyperactivity in open field, and male mice show higher levels of anxiety as determined by the light dark emergence test (Stark et al., 2008). Additionally, lower levels of miRNAs, and synaptic defects in the hippocampus were identified in *Df(16)A+/-* mice, which are suggested to contribute to some of the cognitive defects found in these mice (Mukai et al., 2008, Stark et al., 2008).

DISC1

DISC1 (Disrupted in Schizophrenia 1) was initially identified as a putative susceptibility gene through analysis of a Scottish pedigree with a (1; 11) (q42.1; q14.3) translocation that resulted in the disruption of the *DISC1* gene (Millar et al., 2000). Family members carrying the deletion were affected with SZ, depression, and BD (Ishizuka et al., 2006). Additional independent linkage and association studies in diverse populations have confirmed *DISC1* as a susceptibility gene for SZ (Palo et al., 2007). Several mouse models have been generated that disrupt *DISC1* to evaluate its role in SZ including a truncated *DISC1* (*DISC1_{tr}*) mimicking the break in the Scottish pedigree, a missense *DISC1* (*DISC1_{L100P}*), and a dominant negative *DISC1* (*DN-DISC1*) driven by the CaMKII promoter (Clapcote et al., 2007, Hikida et al., 2007, Shen et al., 2008).

The DISC1^{tr} mice exhibit several SZ hallmarks including increased lateral ventricles, decreased cerebral cortex volume, and decreased parvalbumin (PV) expression in the medial prefrontal cortex (mPFC) (Shen et al., 2008). Additionally, these mice exhibit decreased LI, and increased immobility in forced swim test (Shen et al., 2008). This model shows promise as it mimics a break point found in human patients, and possesses some SZ-like pathology.

The DISC1^{L100P} mice also exhibit neuro-anatomical changes seen in schizophrenia patients, and exhibit behaviors that may be relevant to SZ including decreased PPI, decreased LI, increased activity in the open field, and decreased performance in the T-maze (Clapcote et al., 2007). Importantly, treatment with antipsychotics such as haloperidol and clozapine correct the deficits in PPI, LI, and reduce mobility in these mice (Clapcote et al., 2007). While this model is a promising model of SZ it does not reflect a mutation found in human patients.

The DN-DICS1 showed increased volume of the left lateral ventricle, and has decreased immunoreactivity of PV positive inhibitory neurons (Hikida et al., 2007). These mice exhibited hyperactivity in the open field, increased immobility in the forced swim test, and a small deficit in PPI at 74 decibels only (Hikida et al., 2007). This mouse did not show any difference in Y-maze, Morris water maze, or social paradigms (Hikida et al., 2007). Overall, DISC1 transgenic mouse models show promise as models of SZ.

Other SZ models

Deficits in glutamatergic transmission through the NMDAR have been implicated in the expression of SZ (Olney et al., 1999). This hypothesis emerged after the discovery that phencyclidine (PCP), which primarily acts through blockade of the NMDAR, led to a SZ-like psychosis and the exacerbation of symptoms in SZ patients (Lodge and Anis, 1982, Luby et al., 1959). Later studies showed that the use of NMDAR antagonist such as MK-801 also induced psychosis that could be reversed by the administration of antipsychotics such as clozapine (Olney et al., 1999). Additional studies using brain imaging, postmortem staining, and genetic manipulation have further implicated NMDAR hypofunction in SZ (Kehrer et al., 2008). One model which reduces expression of the NR1 subunit of the NMDAR (NR1_{hypo}) generated by Mohn et al. shows increased sensitivity to PCP, increased open field activity, decreased social investigation in the resident intruder test, and decreased PPI that is reversed by treatment with antipsychotics (Duncan et al., 2006b, Duncan et al., 2006a, Mohn et al., 1999, Moy et al., 2006).

Recently, generation of a transgenic mouse model selectively deleting NR1 expression in PV positive neurons of the forebrain show increased activity in the open field, increased anxiety in the elevated plus maze, decreased PPI, mild anhedonia in the saccharine-preference test after social isolation, and impaired nesting behavior (Belforte et al., 2010). Thus the glutamate hypothesis and the role of the NMDAR in SZ is a promising model for studying SZ.

Many other transgenic mouse models are currently being characterized as models of SZ including ErbB4, Adenosine Kinase, Complexin 1, mGluR1, and many more. Additionally, there are many developmental, drug induced, and lesion preparation models that are outside the scope of this review. For a comprehensive list of mouse models of schizophrenia go to http://www.schizophreniaforum.org/res/models/Animal_Models_04_09.pdf.

VI. Future Directions

Transgenic animal models are important tools for studying the molecular, cellular, and circuitry mechanisms of childhood onset psychiatric disorders. In this review we attempted

to introduce current transgenic models for ADHD, ASD, Mood Disorders, OCD, and SZ. Here we will focus on general future directions for designing useful animal models. We will highlight the newest technologies available and discuss the advantage and limitations of these technologies.

Modeling Human Variations/Mutations in Mice

Many of the models presented in this review aim to delete or overexpress genes implicated in childhood onset psychiatric disorders. These mouse models have been very helpful in confirming the involvement of these genes in psychiatric disorders, and in some cases have provided insight into specific brain regions that may be involved in the expression of some of the disorders features. However, in many human patients, psychiatric disorders do not arise from a complete deletion or duplication of a gene. Human genetic studies have identified many rare variations or mutations within genes of interest which are thought to contribute to the expression of psychiatric disorders (Hudziak and Faraone, 2010). Some labs have begun to generate mice that mimic break points or variations observed in human patients, and these models show promise as models for their respective disorders (Chadman et al., 2008, Shen et al., 2008, Tabuchi et al., 2007, Veenstra-Vanderweele et al., 2009). Thus, generating mouse models that replace the endogenous gene with a variation or mutation identified in human populations will reflect conditions observed in human patients, and may allow for better elucidation of the etiology of these childhood onset psychiatric disorders.

New Tools for the Study of Brain Function

Cre-Lox System—The concept of using cre-lox systems to target specific brain regions or neuronal populations is not new, however this technique is continually advancing. Cre can be expressed either globally or conditionally in subpopulations of cells/organs (Gaveriaux-Ruff and Kieffer, 2007, Wolf and Woodside, 2005). Currently, traditional and inducible cre lines are available (Heldt and Ressler, 2009, Utomo et al., 1999). Traditional cre lines express cre in the temporal and spatial pattern of the selected promoter. Inducible cre lines express cre in the specific pattern after administration of a drug such as tamoxifen (Cre-ER) (Feil et al., 1997). As the temporal and spatial expression patterns of more genes are characterized, the available cre-lines will greatly increase. Many groups, along with gene expression nervous system atlas (GENSAT) project and Allen Brain Institute, have characterized hundreds of genes and their expression patterns to date. The advantage of this method over a global knockout/over-expression is that using specific promoters allow for targeting and manipulation of specific brain regions or sub-populations of neurons. Importantly, this method can be beneficial when global effects result in lethality or developmental problems not associated with the disorder of interest. One limitation of this approach is that genes are generally expressed in many brain areas. Thus, while scientists can target selected sub-populations of neurons using different promoters, it is difficult to target specific brain regions without expression in other areas using transgenic cre mouse lines. Viral injection of cre driven by a specific promoter circumvents this problem. Additionally, the expression pattern has not been characterized for all genes, therefore a transgenic cre mouse line may not currently exist that targets the specific population of interest. As more and more genes are characterized, this limitation will be marginalized. Another issue to be mindful of in using this technique is that often cre-lines do not affect 100% of the target population, and sometimes ectopic expression of cre occurs. Careful characterization of new cre-lines using reporter lines that express fluorescence in the presence of cre will be required to verify the expression pattern (Wang, 2009).

One advancement to the cre-lox system is the inverted and double floxed with LoxP and mutant LoxP (mLoxP) FLEX switch (Atasoy et al., 2008, Nyabi et al., 2009, Schnutgen et

al., 2003). This system allows for flanking of a genomic region of interest, where in the presence of Cre a region of DNA is inverted to change the expression pattern of the gene of interest. For example, exons can be inverted leading to the generation of a knockout mouse in the absence of cre. In the presence of cre the exons will be inverted again restoring protein expression. Additionally, this method can be used to flank exons with loxP/mloxP sites where in the absence of cre there is normal gene expression and in the presence of cre the exons are inverted resulting in a loss of gene expression. Thus, the FLEX method can be used to generate a cre-induced gene rescue using the original gene locus as well as a traditional cre-induced knockout. The FLEX method maintains the advantages of using cre-lines including temporal and spatial control over gene replacement/knockout expression.

Optogenetics—Another new method available is optogenetics, channelrhodopsin and halorhodopsin (Arenkiel et al., 2007, Zhang et al., 2008, Zhao et al., 2008). Channelrhodopsin is a non-selective cation channel that is activated by blue light (473nm), which leads to neuronal activation. Halorhodopsin is a chloride pump that is activated by yellow light (580nm) and leads to neuronal silencing. These channels can be expressed using any of the currently available techniques including cre-lox, viral delivery, or knock-in. The advantage of this method is the ability to stimulate or silence specific neurons rapidly and effectively both in vivo and in vitro (Airan et al., 2009, Cardin et al., 2009, Cardin et al., 2010, Zhang et al., 2010). Importantly, in vivo recording of neuronal activation by field local potentials (FLPs) or specific regulation of single neurons by whole cell recordings is a rapidly advancing technique used to study psychiatric disorders in animal models (Stuber, 2010, Zhang et al., 2010). These recording techniques allow for the study of neuronal signaling in an intact system, and can be used in both anesthetized and awake behaving animals (Adamantidis et al., 2010, Cardin et al., 2009). Optogenetics facilitates the effectiveness of these recording techniques by allowing for rapid and precise stimulation/silencing of specific neurons or brain regions to generate specific firing patterns (Cardin et al., 2009, Cardin et al., 2010). The greatest limitation of this technique is that light is required to activate the channels, therefore direct access to the brain region of interest is necessary. Currently, in vivo experiments require surgery to place cannulas and attachment of a fiberoptic cable to deliver the light pulses. Thus, damage to other brain regions is a confounding issue. Additionally, the ability to perform behavioral studies is severely limited due to the fiberoptic cables attached to the head of the animal.

Chemicogenetics—The final method we will introduce is chemicogenetics (Conklin et al., 2008, Dong et al., 2010, Nichols and Roth, 2009, Pei et al., 2010). One example is the “designer receptor exclusively activated by a designer drug” (DREADD) strategy. DREADD receptors are mutated muscarinic acetylcholine (mACh) receptors that no longer respond to Ach and are selectively activated by clozapine-N-oxide (CNO) (Alexander et al., 2009, Armbruster et al., 2007). M4 receptors are G_i coupled receptors that leads to neuronal silencing by inhibiting adenylate cyclase (AC) levels and prolonging potassium channel, non-specific cation channel and transient receptor channel opening (Eglen, 2006). The M3 receptor is a G_q coupled receptors that leads to neuronal activation by mobilizing phosphoinositides and decreasing intracellular calcium levels (Eglen, 2006). Thus, M4-DREADDs lead to neuronal silencing while the M3-DREADDs result in neuronal activation. DREADD receptors, like channelrhodopsin and halorhodopsin can be introduced using any of the currently available techniques. Importantly, this method can be used in vivo as CNO can pass through the blood brain barrier (Alexander et al., 2009). Advantages to this method are that behavioral studies are not limited as there is no external equipment attached to the mouse. Additionally, CNO is completely inert in cells not expressing DREADD receptors, therefore complications due to drug related side effects are not an issue. Thus, this technique shows great promise for behavioral studies.

One limitation for this method is that delivery of CNO is on a much slower time scale than the rapid control of optogenetics so studies of direct stimulation/silencing effects on signaling are limited in this model. A second limitation is that the method has not been characterized in all cell types and may not work in all systems due to differential expression of signaling pathways required for DREADD receptor-mediated neuronal activation/silencing.

VII. Conclusions

In conclusion, studies using animal models have greatly increased our understanding of childhood onset psychiatric disorders. As discussed earlier, it is impossible to model an entire psychiatric disorder in a single mouse model, however these models can be very useful in characterizing a specific behavior or physical feature of a disorder. Additionally, many characteristics of childhood onset psychiatric disorders are shared between disorders. For example, repetitive behaviors are seen in both OCD and ASD. Therefore, when considering the validity of a transgenic mouse model, one should evaluate the validity for select behaviors or a particular feature rather than the validity of a mouse for a particular psychiatric disorder. Thus far, animal models have played important roles in validating candidate genes related to specific disorders, identifying and confirming the involvement of signaling pathways in specific behaviors/disorders, and in identifying potential targets for development of new therapeutics. One future goal is to compare different models that share a common behavior or characteristic to identify common neuronal circuitry defects involved in the expression of that behavior. The newest technologies discussed in this review can then be used to test and confirm the involvement of a particular circuitry network or population of neurons allowing for a deeper understanding of the underlying causes of psychiatric disorders.

Acknowledgments

We would like to thank the Feng lab and Ramona Rodriguiz for their critical comments and suggestions. We would like to acknowledge support from NIH postdoctoral training program fellowship (HRR), NIMH, The Hartwell Foundation, The Simons Foundation, The McKnight Foundation, and DIBS (GF).

References

- Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, Mathews CA, Pauls DL, Rasin MR, Gunel M, et al. Sequence variants in *SLITRK1* are associated with Tourette's syndrome. *Science*. 2005; 310:317–320. [PubMed: 16224024]
- Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. *Nat Rev Genet*. 2008; 9:341–355. [PubMed: 18414403]
- Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. *J Clin Psychopharmacol*. 1998; 18:185–192. [PubMed: 9617976]
- Adamantidis A, Carter MC, de Lecea L. Optogenetic deconstruction of sleep-wake circuitry in the brain. *Front Mol Neurosci*. 2010; 2:31. [PubMed: 20126433]
- Airan RD, Thompson KR, Fenno LE, Bernstein H, Deisseroth K. Temporally precise in vivo control of intracellular signalling. *Nature*. 2009
- Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. *Neuron*. 2009; 63:27–39. [PubMed: 19607790]
- Altamura C, Dell'Acqua ML, Moessner R, Murphy DL, Lesch KP, Persico AM. Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. *Cereb Cortex*. 2007; 17:1394–1401. [PubMed: 16905592]

- Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. *Proc Natl Acad Sci U S A*. 2010; 107:4389–4394. [PubMed: 20160081]
- APA. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). American Psychiatric Association; Washington, DC: 2000.
- Arenkiel BR, Peca J, Davison IG, Feliciano C, Deisseroth K, Augustine GJ, Ehlers MD, Feng G. In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. *Neuron*. 2007; 54:205–218. [PubMed: 17442243]
- Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl Acad Sci U S A*. 2007; 104:5163–5168. [PubMed: 17360345]
- Aruga J, Mikoshiba K. Identification and characterization of Slitrk, a novel neuronal transmembrane protein family controlling neurite outgrowth. *Mol Cell Neurosci*. 2003; 24:117–129. [PubMed: 14550773]
- Atasoy D, Aponte Y, Su HH, Sternson SM. A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. *J Neurosci*. 2008; 28:7025–7030. [PubMed: 18614669]
- Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. *Brain Res Bull*. 2001; 56:413–424. [PubMed: 11750787]
- Baader SL, Sanlioglu S, Berrebi AS, Parker-Thornburg J, Oberdick J. Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions. *J Neurosci*. 1998; 18:1763–1773. [PubMed: 9465001]
- Barbier E, Wang JB. Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. *BMC Neurosci*. 2009; 10:132. [PubMed: 19912621]
- Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A, Shippenberg T, Wang JB. Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. *Neuropsychopharmacology*. 2007; 32:1774–1782. [PubMed: 17203012]
- Barnett JH, Smoller JW. The genetics of bipolar disorder. *Neuroscience*. 2009; 164:331–343. [PubMed: 19358880]
- Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. *Neuropsychopharmacology*. 2004; 29:221–228. [PubMed: 14603268]
- Baumgardner TL, Singer HS, Denckla MB, Rubin MA, Abrams MT, Colli MJ, Reiss AL. Corpus callosum morphology in children with Tourette syndrome and attention deficit hyperactivity disorder. *Neurology*. 1996; 47:477–482. [PubMed: 8757024]
- Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci*. 2004; 27:370–377. [PubMed: 15219735]
- Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. *Nat Neurosci*. 2010; 13:76–83. [PubMed: 19915563]
- Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, Mobley WC, Francke U. Widespread changes in dendritic and axonal morphology in *Mecp2*-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. *J Comp Neurol*. 2009; 514:240–258. [PubMed: 19296534]
- Bellodi L, Cavallini MC, Bertelli S, Chiapparino D, Riboldi C, Smeraldi E. Morbidity risk for obsessive-compulsive spectrum disorders in first-degree relatives of patients with eating disorders. *Am J Psychiatry*. 2001; 158:563–569. [PubMed: 11282689]
- Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, Kamdar S, Bruse SE, Tischfield S, Smith BJ, Zimmerman RA, et al. Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus. *Am J Hum Genet*. 2005; 77:851–868. [PubMed: 16252243]
- Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-

- methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. *Mol Pharmacol.* 1998; 53:649–655. [PubMed: 9547354]
- Bennetto L, Kuschner ES, Hyman SL. Olfaction and taste processing in autism. *Biol Psychiatry.* 2007; 62:1015–1021. [PubMed: 17572391]
- Benno R, Smirnova Y, Vera S, Liggett A, Schanz N. Exaggerated responses to stress in the BTBR T +tf/J mouse: an unusual behavioral phenotype. *Behav Brain Res.* 2009; 197:462–465. [PubMed: 18977396]
- Berridge KC, Aldridge JW, Houchard KR, Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. *BMC Biol.* 2005; 3:4. [PubMed: 15710042]
- Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. *Trends Neurosci.* 2009; 32:402–412. [PubMed: 19541375]
- Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. *Lancet.* 2005; 366:237–248. [PubMed: 16023516]
- Bielsky IF, Hu SB, Ren X, Terwilliger EF, Young LJ. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. *Neuron.* 2005; 47:503–513. [PubMed: 16102534]
- Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. *Neuropsychopharmacology.* 2004; 29:483–493. [PubMed: 14647484]
- Blatt GJ. GABAergic cerebellar system in autism: a neuropathological and developmental perspective. *Int Rev Neurobiol.* 2005; 71:167–178. [PubMed: 16512350]
- Blundell J, Blaiss CA, Etherton MR, Espinosa F, Tabuchi K, Walz C, Bolliger MF, Sudhof TC, Powell CM. Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. *J Neurosci.* 2010; 30:2115–2129. [PubMed: 20147539]
- Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. *J Psychiatry Neurosci.* 2000; 25:446–458. [PubMed: 11109296]
- Bolton PF, Veltman MW, Weisblatt E, Holmes JR, Thomas NS, Youings SA, Thompson RJ, Roberts SE, Dennis NR, Browne CE, et al. Chromosome 15q11–13 abnormalities and other medical conditions in individuals with autism spectrum disorders. *Psychiatr Genet.* 2004; 14:131–137. [PubMed: 15318025]
- Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, Baroncini A, Prampero T, Zuffardi O. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. *J Med Genet.* 2006; 43:822–828. [PubMed: 16284256]
- Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, Wetsel WC, Missale C, Caron MG. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. *Neuron.* 1997; 19:127–138. [PubMed: 9247269]
- Bradley W. The behavior of children receiving benzedrine. *American Journal of Psychiatry.* 1937; 94:577–587.
- Brennan FX, Albeck DS, Paylor R. Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. *Genes Brain Behav.* 2006; 5:467–471. [PubMed: 16923151]
- Brioni JD, O'Neill AB, Kim DJ, Decker MW. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. *Eur J Pharmacol.* 1993; 238:1–8. [PubMed: 8405072]
- Brodkin ES. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008). *Behav Neurosci.* 2008; 122:483–489. [PubMed: 18410188]
- Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. *Cell.* 2001; 107:477–487. [PubMed: 11719188]
- Bruno KJ, Freet CS, Twining RC, Egami K, Grigson PS, Hess EJ. Abnormal latent inhibition and impulsivity in coloboma mice, a model of ADHD. *Neurobiol Dis.* 2007; 25:206–216. [PubMed: 17064920]

- Bruno KJ, Hess EJ. The alpha(2C)-adrenergic receptor mediates hyperactivity of coloboma mice, a model of attention deficit hyperactivity disorder. *Neurobiol Dis.* 2006; 23:679–688. [PubMed: 16839770]
- Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet.* 2005; 42:318–321. [PubMed: 15805158]
- Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsater H, Rastam M, Smith CJ, Silverman JM, et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. *Am J Med Genet B Neuropsychiatr Genet.* 2007; 144B:484–491. [PubMed: 17427195]
- Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, Reichert J, Cook EH Jr, Fang Y, Song CY, Vitale R. Association between a GABRB3 polymorphism and autism. *Mol Psychiatry.* 2002; 7:311–316. [PubMed: 11920158]
- Caldwell HK, Wersinger SR, Young WS 3rd. The role of the vasopressin 1b receptor in aggression and other social behaviours. *Prog Brain Res.* 2008; 170:65–72. [PubMed: 18655872]
- Campbell KM, de Lecea L, Severynse DM, Caron MG, McGrath MJ, Sparber SB, Sun LY, Burton FH. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. *J Neurosci.* 1999; 19:5044–5053. [PubMed: 10366637]
- Canli T, Omura K, Haas BW, Fallgatter A, Constable RT, Lesch KP. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. *Proc Natl Acad Sci U S A.* 2005; 102:12224–12229. [PubMed: 16093315]
- Capecchi MR. Hox genes and mammalian development. *Cold Spring Harb Symp Quant Biol.* 1997; 62:273–281. [PubMed: 9598361]
- Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, Moore CI. Driving fast-spiking cells induces gamma rhythm and controls sensory responses. *Nature.* 2009; 459:663–667. [PubMed: 19396156]
- Cardin JA, Carlen M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, Moore CI. Targeted optogenetic stimulation and recording of neurons in vivo using cell-type-specific expression of Channelrhodopsin-2. *Nat Protoc.* 2010; 5:247–254. [PubMed: 20134425]
- Carey, G.; Gottesman, I. Twin and Family studies of anxiety, phobic, and obsessive disorders. In: KLEIN, D.; RABKIN, J., editors. *Anxiety: New Research and Changing Concepts.* Raven; New York: 1981. p. 117-136.
- Carroll JC, Boyce-Rustay JM, Millstein R, Yang R, Wiedholz LM, Murphy DL, Holmes A. Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. *Behav Genet.* 2007; 37:214–222. [PubMed: 17177116]
- Carter CS, Grippo AJ, Pournajafi-Nazarloo H, Ruscio MG, Porges SW. Oxytocin, vasopressin and sociality. *Prog Brain Res.* 2008; 170:331–336. [PubMed: 18655893]
- CDC. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. *MMWR Surveill Summ.* 2009; 58:1–20.
- Chadman KK, Gong S, Scattoni ML, Boltuck SE, Gandhi SU, Heintz N, Crawley JN. Minimal aberrant behavioral phenotypes of neuroligin-3 R451C knockin mice. *Autism Res.* 2008; 1:147–158. [PubMed: 19360662]
- Chahrouh M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science.* 2008; 320:1224–1229. [PubMed: 18511691]
- Chan JP, Unger TJ, Byrnes J, Rios M. Examination of behavioral deficits triggered by targeting Bdnf in fetal or postnatal brains of mice. *Neuroscience.* 2006; 142:49–58. [PubMed: 16844311]
- Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron.* 2006; 49:341–348. [PubMed: 16446138]
- Cheh MA, Millonig JH, Roselli LM, Ming X, Jacobsen E, Kamdar S, Wagner GC. En2 knockout mice display neurobehavioral and neurochemical alterations relevant to autism spectrum disorder. *Brain Res.* 2006; 1116:166–176. [PubMed: 16935268]

- Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. *J Neurochem*. 1999; 72:1327–1330. [PubMed: 10037507]
- Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. *Nat Genet*. 2001a; 27:327–331. [PubMed: 11242118]
- Chen SK, Tvrdik P, Peden E, Cho S, Wu S, Spangrude G, Capecchi MR. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. *Cell*. 2010; 141:775–785. [PubMed: 20510925]
- Chen W, Hu LA, Semenov MV, Yanagawa S, Kikuchi A, Lefkowitz RJ, Miller WE. beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. *Proc Natl Acad Sci U S A*. 2001b; 98:14889–14894. [PubMed: 11742073]
- Chou-Green JM, Holscher TD, Dallman MF, Akana SF. Compulsive behavior in the 5-HT_{2C} receptor knockout mouse. *Physiol Behav*. 2003a; 78:641–649. [PubMed: 12782219]
- Chou-Green JM, Holscher TD, Dallman MF, Akana SF. Repeated stress in young and old 5-HT_{2C} receptor knockout mice. *Physiol Behav*. 2003b; 79:217–226. [PubMed: 12834793]
- Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, et al. Behavioral phenotypes of Disc1 missense mutations in mice. *Neuron*. 2007; 54:387–402. [PubMed: 17481393]
- Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. *J Med Genet*. 2003; 40:87–95. [PubMed: 12566516]
- Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette's syndrome. *Lancet*. 1979; 2:551–553. [PubMed: 89558]
- Conklin BR, Hsiao EC, Claeysen S, Dumuis A, Srinivasan S, Forsayeth JR, Guettier JM, Chang WC, Pei Y, McCarthy KD, et al. Engineering GPCR signaling pathways with RASSLs. *Nat Methods*. 2008; 5:673–678. [PubMed: 18668035]
- Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG, Neuman RJ, Deuel RM. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. *Biol Psychiatry*. 2006; 59:354–363. [PubMed: 16181614]
- Correa-Cerro LS, Wassif CA, Kratz L, Miller GF, Munasinghe JP, Grinberg A, Fliesler SJ, Porter FD. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. *Hum Mol Genet*. 2006; 15:839–851. [PubMed: 16446309]
- Courchesne E. Brain development in autism: early overgrowth followed by premature arrest of growth. *Ment Retard Dev Disabil Res Rev*. 2004; 10:106–111. [PubMed: 15362165]
- Courchesne E, Redcay E, Kennedy DP. The autistic brain: birth through adulthood. *Curr Opin Neurol*. 2004; 17:489–496. [PubMed: 15247547]
- Craig AM, Kang Y. Neurexin-neuroigin signaling in synapse development. *Curr Opin Neurobiol*. 2007; 17:43–52. [PubMed: 17275284]
- Crawley JN. *What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice*. John Wiley, & Sons; Hoboken, NJ: 2007.
- Crawley JN, Chen T, Puri A, Washburn R, Sullivan TL, Hill JM, Young NB, Nadler JJ, Moy SS, Young LJ, et al. Social approach behaviors in oxytocin knockout mice: comparison of two independent lines tested in different laboratory environments. *Neuropeptides*. 2007; 41:145–163. [PubMed: 17420046]
- Cusmano-Ozog K, Manning MA, Hoyme HE. 22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay. *Am J Med Genet C Semin Med Genet*. 2007; 145C:393–398. [PubMed: 17926345]
- D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP. Mildly impaired water maze performance in male Fmr1 knockout mice. *Neuroscience*. 1997; 76:367–376. [PubMed: 9015322]
- Dani VS, Nelson SB. Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome. *J Neurosci*. 2009; 29:11263–11270. [PubMed: 19741133]

- Daws LC, Munn JL, Valdez MF, Frosto-Burke T, Hensler JG. Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): in vivo studies in BDNF-deficient mice. *J Neurochem.* 2007; 101:641–651. [PubMed: 17254018]
- de Kloet ER, Oitzl MS, Joels M. Stress and cognition: are corticosteroids good or bad guys? *Trends Neurosci.* 1999; 22:422–426. [PubMed: 10481183]
- de Vries GJ, Miller MA. Anatomy and function of extrahypothalamic vasopressin systems in the brain. *Prog Brain Res.* 1998; 119:3–20. [PubMed: 10074777]
- de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in *Fmr1* KO mice. *Neurobiol Dis.* 2008; 31:127–132. [PubMed: 18571098]
- Dell'Osso B, Altamura AC, Mundo E, Marazziti D, Hollander E. Diagnosis and treatment of obsessive-compulsive disorder and related disorders. *Int J Clin Pract.* 2007; 61:98–104. [PubMed: 17229184]
- DeLorey TM, Handforth A, Anagnostaras SG, Homanics GE, Minassian BA, Asatourian A, Fanselow MS, Delgado-Escueta A, Ellison GD, Olsen RW. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. *J Neurosci.* 1998; 18:8505–8514. [PubMed: 9763493]
- DeLorey TM, Sahbaie P, Hashemi E, Homanics GE, Clark JD. *Gabrb3* gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. *Behav Brain Res.* 2008; 187:207–220. [PubMed: 17983671]
- DeVries AC, Young WS 3rd, Nelson RJ. Reduced aggressive behaviour in mice with targeted disruption of the oxytocin gene. *J Neuroendocrinol.* 1997; 9:363–368. [PubMed: 9181490]
- Dick DM, Riley B, Kendler KS. Nature and nurture in neuropsychiatric genetics: where do we stand? *Dialogues Clin Neurosci.* 2010; 12:7–23. [PubMed: 20373663]
- Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. *J Cell Sci.* 2003; 116:1175–1186. [PubMed: 12615961]
- Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. Correction of fragile X syndrome in mice. *Neuron.* 2007; 56:955–962. [PubMed: 18093519]
- Dong S, Rogan SC, Roth BL. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs. *Nat Protoc.* 2010; 5:561–573. [PubMed: 20203671]
- Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E. Neurotrophic effects of Cerebrolysin in the *Mecp2(308/Y)* transgenic model of Rett syndrome. *Acta Neuropathol.* 2008; 116:425–437. [PubMed: 18600331]
- Dudanova I, Tabuchi K, Rohlmann A, Sudhof TC, Missler M. Deletion of alpha-neurexins does not cause a major impairment of axonal pathfinding or synapse formation. *J Comp Neurol.* 2007; 502:261–274. [PubMed: 17347997]
- Duncan GE, Moy SS, Lieberman JA, Koller BH. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. *Psychopharmacology (Berl).* 2006a; 184:190–200. [PubMed: 16362405]
- Duncan GE, Moy SS, Lieberman JA, Koller BH. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. *Pharmacol Biochem Behav.* 2006b; 85:481–491. [PubMed: 17097724]
- Dykens EM, Sutcliffe JS, Levitt P. Autism and 15q11-q13 disorders: behavioral, genetic, and pathophysiological issues. *Ment Retard Dev Disabil Res Rev.* 2004; 10:284–291. [PubMed: 15666333]
- Easton A, Arbuzova J, Turek FW. The circadian Clock mutation increases exploratory activity and escape-seeking behavior. *Genes Brain Behav.* 2003; 2:11–19. [PubMed: 12882315]
- Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. *Auton Autacoid Pharmacol.* 2006; 26:219–233. [PubMed: 16879488]
- Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ, Barci BM, Torrey EF. Meta-analysis of 12 genomic studies in bipolar disorder. *J Mol Neurosci.* 2007; 31:221–243. [PubMed: 17726228]

- Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. *Proc Natl Acad Sci U S A*. 2009; 106:17998–18003. [PubMed: 19822762]
- Fan X, Xu M, Hess EJ. D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD. *Neurobiol Dis*. 2010; 37:228–236. [PubMed: 19840852]
- Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. *Biochem Biophys Res Commun*. 1997; 237:752–757. [PubMed: 9299439]
- Ferguson JN, Young LJ, Hearn EF, Matzuk MM, Insel TR, Winslow JT. Social amnesia in mice lacking the oxytocin gene. *Nat Genet*. 2000; 25:284–288. [PubMed: 10888874]
- Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. *Proc Natl Acad Sci U S A*. 1998; 95:6965–6970. [PubMed: 9618522]
- Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik YK, Glossmann H, Utermann G, Moebius FF. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. *Proc Natl Acad Sci U S A*. 1998; 95:8181–8186. [PubMed: 9653161]
- Forero DA, Arboleda GH, Vasquez R, Arboleda H. Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. *J Psychiatry Neurosci*. 2009; 34:361–366. [PubMed: 19721846]
- Frade JM, Barde YA. Microglia-derived nerve growth factor causes cell death in the developing retina. *Neuron*. 1998; 20:35–41. [PubMed: 9459440]
- Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. *Mol Psychiatry*. 2007; 12:2–22. [PubMed: 17033636]
- Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. *Proc Natl Acad Sci U S A*. 2001; 98:11047–11054. [PubMed: 11572967]
- Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. *Science*. 1999; 283:397–401. [PubMed: 9888856]
- Garber KB, Visootsak J, Warren ST. Fragile X syndrome. *Eur J Hum Genet*. 2008; 16:666–672. [PubMed: 18398441]
- Gaveriaux-Ruff C, Kieffer BL. Conditional gene targeting in the mouse nervous system: Insights into brain function and diseases. *Pharmacol Ther*. 2007; 113:619–634. [PubMed: 17289150]
- Gelenberg AJ, Carroll JA, Baudhuin MG, Jefferson JW, Greist JH. The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. *J Clin Psychiatry*. 1989; 50(Suppl):17–22. discussion 45–17. [PubMed: 2689433]
- Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. *Biol Psychiatry*. 2006; 59:468–476. [PubMed: 16199017]
- Gerrow K, Romorini S, Nabi SM, Colicos MA, Sala C, El-Husseini A. A preformed complex of postsynaptic proteins is involved in excitatory synapse development. *Neuron*. 2006; 49:547–562. [PubMed: 16476664]
- Geyer MA. Developing translational animal models for symptoms of schizophrenia or bipolar mania. *Neurotox Res*. 2008; 14:71–78. [PubMed: 18790726]
- Giros B, Caron MG. Molecular characterization of the dopamine transporter. *Trends Pharmacol Sci*. 1993; 14:43–49. [PubMed: 8480373]
- Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature*. 1996; 379:606–612. [PubMed: 8628395]
- Glaze DG. Rett syndrome: of girls and mice--lessons for regression in autism. *Ment Retard Dev Disabil Res Rev*. 2004; 10:154–158. [PubMed: 15362175]
- Goddard AW, Shekhar A, Whiteman AF, McDougale CJ. Serotonergic mechanisms in the treatment of obsessive-compulsive disorder. *Drug Discov Today*. 2008; 13:325–332. [PubMed: 18405845]

- Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP. PTEN mutation in a family with Cowden syndrome and autism. *Am J Med Genet.* 2001; 105:521–524. [PubMed: 11496368]
- Goffinet AM. Events governing organization of postmigratory neurons: studies on brain development in normal and reeler mice. *Brain Res.* 1984; 319:261–296. [PubMed: 6383524]
- Grabe HJ, Ruhrmann S, Ettelt S, Buhtz F, Hochrein A, Schulze-Rauschenbach S, Meyer K, Kraft S, Reck C, Pukrop R, et al. Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. *Am J Psychiatry.* 2006; 163:1986–1992. [PubMed: 17074951]
- Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. *Neuron.* 2000; 28:343–347. [PubMed: 11144344]
- Greenberg ME, Xu B, Lu B, Hempstead BL. New insights in the biology of BDNF synthesis and release: implications in CNS function. *J Neurosci.* 2009; 29:12764–12767. [PubMed: 19828787]
- Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in mice. *Neuron.* 2002; 33:23–34. [PubMed: 11779477]
- Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC, Waldon Z, Maehr R, et al. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. *Cell.* 2010; 140:704–716. [PubMed: 20211139]
- Gregory SG, Connelly JJ, Towers AJ, Johnson J, Biscocho D, Markunas CA, Lintas C, Abramson RK, Wright HH, Ellis P, et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. *BMC Med.* 2009; 7:62. [PubMed: 19845972]
- Gross GA, Imamura T, Luedke C, Vogt SK, Olson LM, Nelson DM, Sadovsky Y, Muglia LJ. Opposing actions of prostaglandins and oxytocin determine the onset of murine labor. *Proc Natl Acad Sci U S A.* 1998; 95:11875–11879. [PubMed: 9751758]
- Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. *Science.* 2007; 315:1143–1147. [PubMed: 17289941]
- Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. *Nat Genet.* 2001; 27:322–326. [PubMed: 11242117]
- Hall FS, Li XF, Randall-Thompson J, Sora I, Murphy DL, Lesch KP, Caron M, Uhl GR. Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. *Neuroscience.* 2009; 162:870–880. [PubMed: 19482066]
- Hauser P, McMillin JM, Bhatara VS. Resistance to thyroid hormone: implications for neurodevelopmental research on the effects of thyroid hormone disruptors. *Toxicol Ind Health.* 1998; 14:85–101. [PubMed: 9460171]
- Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, Chattarji S, Tonegawa S. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. *Proc Natl Acad Sci U S A.* 2007; 104:11489–11494. [PubMed: 17592139]
- Hazlett HC, Poe M, Gerig G, Smith RG, Provenzale J, Ross A, Gilmore J, Piven J. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. *Arch Gen Psychiatry.* 2005; 62:1366–1376. [PubMed: 16330725]
- Heikkila RE, Orlansky H, Mytilineou C, Cohen G. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. *J Pharmacol Exp Ther.* 1975; 194:47–56. [PubMed: 1151755]
- Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. *Genes Brain Behav.* 2007; 6:491–496. [PubMed: 17451451]
- Heldt SA, Ressler KJ. The Use of Lentiviral Vectors and Cre/loxP to Investigate the Function of Genes in Complex Behaviors. *Front Mol Neurosci.* 2009; 2:22. [PubMed: 20011219]
- Herbert MR, Russo JP, Yang S, Roohi J, Blaxill M, Kahler SG, Cremer L, Hatchwell E. Autism and environmental genomics. *Neurotoxicology.* 2006; 27:671–684. [PubMed: 16644012]
- Hess EJ, Collins KA, Copeland NG, Jenkins NA, Wilson MC. Deletion map of the coloboma (Cm) locus on mouse chromosome 2. *Genomics.* 1994; 21:257–261. [PubMed: 7916325]
- Hess EJ, Collins KA, Wilson MC. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. *J Neurosci.* 1996; 16:3104–3111. [PubMed: 8622140]
- Hess EJ, Jinnah HA, Kozak CA, Wilson MC. Spontaneous locomotor hyperactivity in a mouse mutant with a deletion including the Snap gene on chromosome 2. *J Neurosci.* 1992; 12:2865–2874. [PubMed: 1613559]

- Hess EJ, Rogan PK, Domoto M, Tinker DE, Ladda RL, Ramer JC. Absence of linkage of apparently single gene mediated ADHD with the human syntenic region of the mouse mutant Coloboma. *Am J Med Genet.* 1995; 60:573–579. [PubMed: 8825900]
- Heyser CJ, Wilson MC, Gold LH. Coloboma hyperactive mutant exhibits delayed neurobehavioral developmental milestones. *Brain Res Dev Brain Res.* 1995; 89:264–269.
- Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, Wu D, Xue R, Andrade M, Tankou S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. *Proc Natl Acad Sci U S A.* 2007; 104:14501–14506. [PubMed: 17675407]
- Hill RA, McInnes KJ, Gong EC, Jones ME, Simpson ER, Boon WC. Estrogen deficient male mice develop compulsive behavior. *Biol Psychiatry.* 2007; 61:359–366. [PubMed: 16566897]
- Hill RA, Murray SS, Halley PG, Binder MD, Martin SJ, van den Buuse M. Brain-derived neurotrophic factor expression is increased in the hippocampus of 5-HT(2C) receptor knockout mice. *Hippocampus.* 2010
- Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, Schuette J, Innis J, Marino M, Philippart M, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. *Neurology.* 2001; 56:1486–1495. [PubMed: 11402105]
- Holmes A, Yang RJ, Lesch KP, Crawley JN, Murphy DL. Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. *Neuropsychopharmacology.* 2003; 28:2077–2088. [PubMed: 12968128]
- Holsboer F. The corticosteroid receptor hypothesis of depression. *Neuropsychopharmacology.* 2000; 23:477–501. [PubMed: 11027914]
- Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CE, Korpi ER, Makela R, et al. Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. *Proc Natl Acad Sci U S A.* 1997; 94:4143–4148. [PubMed: 9108119]
- Hranilovic D, Novak R, Babic M, Novokmet M, Bujas-Petkovic Z, Jernej B. Hyperserotonemia in autism: the potential role of 5HT-related gene variants. *Coll Antropol.* 2008; 32(Suppl 1):75–80. [PubMed: 18405062]
- Hu H, Real E, Takamiya K, Kang MG, Ledoux J, Huganir RL, Malinow R. Emotion enhances learning via norepinephrine regulation of AMPA-receptor trafficking. *Cell.* 2007; 131:160–173. [PubMed: 17923095]
- Huang CH, Santangelo SL. Autism and serotonin transporter gene polymorphisms: a systematic review and meta-analysis. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:903–913. [PubMed: 18286633]
- Hudziak JJ, Faraone SV. The new genetics in child psychiatry. *J Am Acad Child Adolesc Psychiatry.* 2010; 49:729–735. [PubMed: 20643308]
- Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, Grafman J. A psychological and neuroanatomical model of obsessive-compulsive disorder. *J Neuropsychiatry Clin Neurosci.* 2008; 20:390–408. [PubMed: 19196924]
- Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, Woodworth MA, Kidd FL, Sung CC, Miyakawa T, Bear MF, et al. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. *J Neurosci.* 2008; 28:1697–1708. [PubMed: 18272690]
- Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. *Cereb Cortex.* 2000; 10:1038–1044. [PubMed: 11007554]
- Ishizuka K, Paek M, Kamiya A, Sawa A. A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. *Biol Psychiatry.* 2006; 59:1189–1197. [PubMed: 16797264]
- Jamain S, Radyushkin K, Hammerschmidt K, Granon S, Boretius S, Varoqueaux F, Ramanantsoa N, Gallego J, Ronnenberg A, Winter D, et al. Reduced social interaction and ultrasonic communication in a mouse model of monogenic heritable autism. *Proc Natl Acad Sci U S A.* 2008; 105:1710–1715. [PubMed: 18227507]
- Jeans AF, Oliver PL, Johnson R, Capogna M, Vikman J, Molnar Z, Babbs A, Partridge CJ, Salehi A, Bengtsson M, et al. A dominant mutation in Snap25 causes impaired vesicle trafficking,

- sensorimotor gating, and ataxia in the blind-drunk mouse. *Proc Natl Acad Sci U S A*. 2007; 104:2431–2436. [PubMed: 17283335]
- Jeffries AR, Curran S, Elmslie F, Sharma A, Wenger S, Hummel M, Powell J. Molecular and phenotypic characterization of ring chromosome 22. *Am J Med Genet A*. 2005; 137:139–147. [PubMed: 16059935]
- Jenike MA. Clinical practice. Obsessive-compulsive disorder. *N Engl J Med*. 2004; 350:259–265. [PubMed: 14724305]
- Jerome LA, Papaioannou VE. DiGeorge syndrome phenotype in mice mutant for the T-box gene, *Tbx1*. *Nat Genet*. 2001; 27:286–291. [PubMed: 11242110]
- Jiang X, Wang J, Luo T, Li Q. Impaired hypothalamic-pituitary-adrenal axis and its feedback regulation in serotonin transporter knockout mice. *Psychoneuroendocrinology*. 2009; 34:317–331. [PubMed: 18980809]
- Jones MD, Hess EJ. Norepinephrine regulates locomotor hyperactivity in the mouse mutant coloboma. *Pharmacol Biochem Behav*. 2003; 75:209–216. [PubMed: 12759129]
- Jones MD, Williams ME, Hess EJ. Abnormal presynaptic catecholamine regulation in a hyperactive SNAP-25-deficient mouse mutant. *Pharmacol Biochem Behav*. 2001; 68:669–676. [PubMed: 11526963]
- Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. Targeted delivery of an *Mecp2* transgene to forebrain neurons improves the behavior of female *Mecp2*-deficient mice. *Hum Mol Genet*. 2008; 17:1386–1396. [PubMed: 18223199]
- Kakiuchi C, Ishigaki S, Oslowski CM, Fonseca SG, Kato T, Urano F. Valproate, a mood stabilizer, induces *WFS1* expression and modulates its interaction with ER stress protein GRP94. *PLoS One*. 2009; 4:e4134. [PubMed: 19125190]
- Kaladchibachi SA, Doble B, Anthopoulos N, Woodgett JR, Manoukian AS. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. *J Circadian Rhythms*. 2007; 5:3. [PubMed: 17295926]
- Kalra SK, Swedo SE. Children with obsessive-compulsive disorder: are they just “little adults”? *J Clin Invest*. 2009; 119:737–746. [PubMed: 19339765]
- Kalueff AV, Fox MA, Gallagher PS, Murphy DL. Hypolocomotion, anxiety and serotonin syndrome-like behavior contribute to the complex phenotype of serotonin transporter knockout mice. *Genes Brain Behav*. 2007; 6:389–400. [PubMed: 16939636]
- Karayiorgou M, Sobin C, Blundell ML, Galke BL, Malinova L, Goldberg P, Ott J, Gogos JA. Family-based association studies support a sexually dimorphic effect of *COMT* and *MAOA* on genetic susceptibility to obsessive-compulsive disorder. *Biol Psychiatry*. 1999; 45:1178–1189. [PubMed: 10331110]
- Kasahara T, Kubota M, Miyauchi T, Noda Y, Mouri A, Nabeshima T, Kato T. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. *Mol Psychiatry*. 2006; 11:577–593. 523. [PubMed: 16619054]
- Katayama K, Yamada K, Ornthalalai VG, Inoue T, Ota M, Murphy NP, Aruga J. *Slitrk1*-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalities. *Mol Psychiatry*. 2010; 15:177–184. [PubMed: 18794888]
- Kato T. Mitochondrial genes in bipolar disorder. *Seishin Shinkeigaku Zasshi*. 2002; 104:509–512. [PubMed: 12373806]
- Kato T, Ishiwata M, Yamada K, Kasahara T, Kakiuchi C, Iwamoto K, Kawamura K, Ishihara H, Oka Y. Behavioral and gene expression analyses of *Wfs1* knockout mice as a possible animal model of mood disorder. *Neurosci Res*. 2008; 61:143–158. [PubMed: 18343518]
- Kato T, Kakiuchi C, Iwamoto K. Comprehensive gene expression analysis in bipolar disorder. *Can J Psychiatry*. 2007; 52:763–771. [PubMed: 18186176]
- Kavaliers M, Colwell DD, Choleris E, Agmo A, Muglia LJ, Ogawa S, Pfaff DW. Impaired discrimination of and aversion to parasitized male odors by female oxytocin knockout mice. *Genes Brain Behav*. 2003; 2:220–230. [PubMed: 12953788]
- Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia. *Front Mol Neurosci*. 2008; 1:6. [PubMed: 18946539]

- Kieseppa T, Partonen T, Haukka J, Kaprio J, Lonnqvist J. High concordance of bipolar I disorder in a nationwide sample of twins. *Am J Psychiatry*. 2004; 161:1814–1821. [PubMed: 15465978]
- Kimber WL, Hsieh P, Hirotsune S, Yuva-Paylor L, Sutherland HF, Chen A, Ruiz-Lozano P, Hoogstraten-Miller SL, Chien KR, Paylor R, et al. Deletion of 150 kb in the minimal DiGeorge/velocardiofacial syndrome critical region in mouse. *Hum Mol Genet*. 1999; 8:2229–2237. [PubMed: 10545603]
- Kimura A, Stevenson PL, Carter RN, Maccoll G, French KL, Paul Simons J, Al-Shawi R, Kelly V, Chapman KE, Holmes MC. Overexpression of 5-HT_{2C} receptors in forebrain leads to elevated anxiety and hypoactivity. *Eur J Neurosci*. 2009; 30:299–306. [PubMed: 19614978]
- King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. *Arch Gen Psychiatry*. 2009; 66:583–590. [PubMed: 19487623]
- King DP, Takahashi JS. Molecular genetics of circadian rhythms in mammals. *Annu Rev Neurosci*. 2000; 23:713–742. [PubMed: 10845079]
- King DP, Vitaterna MH, Chang AM, Dove WF, Pinto LH, Turek FW, Takahashi JS. The mouse Clock mutation behaves as an antimorph and maps within the W19H deletion, distal of Kit. *Genetics*. 1997; 146:1049–1060. [PubMed: 9215907]
- Klein MG, Yao Y, Slosberg ED, Lima CD, Doki Y, Weinstein IB. Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family. *Exp Cell Res*. 1998; 244:26–32. [PubMed: 9770345]
- Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. *Proc Natl Acad Sci U S A*. 1996; 93:8455–8459. [PubMed: 8710892]
- Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. *Cell Signal*. 2005; 17:675–689. [PubMed: 15722192]
- Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, Nowak P, Brus R. Pharmacological models of ADHD. *J Neural Transm*. 2008; 115:287–298. [PubMed: 17994186]
- Krebs MO, Betancur C, Leroy S, Bourdel MC, Gillberg C, Leboyer M. Absence of association between a polymorphic GGC repeat in the 5' untranslated region of the reelin gene and autism. *Mol Psychiatry*. 2002; 7:801–804. [PubMed: 12192627]
- Kuwagata M, Ogawa T, Shioda S, Nagata T. Observation of fetal brain in a rat valproate-induced autism model: a developmental neurotoxicity study. *Int J Dev Neurosci*. 2009; 27:399–405. [PubMed: 19460635]
- Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF. Pten regulates neuronal arborization and social interaction in mice. *Neuron*. 2006; 50:377–388. [PubMed: 16675393]
- Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. *Front Neuroendocrinol*. 2004; 25:150–176. [PubMed: 15589267]
- Langley K, Turic D, Peirce TR, Mills S, Van Den Bree MB, Owen MJ, O'Donovan MC, Thapar A. No support for association between the dopamine transporter (DAT1) gene and ADHD. *Am J Med Genet B Neuropsychiatr Genet*. 2005; 139B:7–10. [PubMed: 16082688]
- Laporte JL, Ren-Patterson RF, Murphy DL, Kalueff AV. Refining psychiatric genetics: from 'mouse psychiatry' to understanding complex human disorders. *Behav Pharmacol*. 2008; 19:377–384. [PubMed: 18690099]
- Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J, Rodd ZA, Paulus M, Geyer MA, Edenberg HJ, et al. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. *Am J Med Genet B Neuropsychiatr Genet*. 2008; 147B:134–166. [PubMed: 18247375]
- Leckman JF, Rauch SL, Mataix-Cols D. Symptom dimensions in obsessive-compulsive disorder: implications for the DSM-V. *CNS Spectr*. 2007; 12:376–387. 400. [PubMed: 17514082]
- Lee HJ, Caldwell HK, Macbeth AH, Young WS 3rd. Behavioural studies using temporal and spatial inactivation of the oxytocin receptor. *Prog Brain Res*. 2008; 170:73–77. [PubMed: 18655873]

- Lieberman P. Human language and our reptilian brain. The subcortical bases of speech, syntax, and thought. *Perspect Biol Med.* 2001; 44:32–51. [PubMed: 11253303]
- Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K, Stevens KE, Maccaferri G, McBain CJ, Sussman DJ, et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. *Cell.* 1997; 90:895–905. [PubMed: 9298901]
- Lindsay EA, Botta A, Jurecic V, Carattini-Rivera S, Cheah YC, Rosenblatt HM, Bradley A, Baldini A. Congenital heart disease in mice deficient for the DiGeorge syndrome region. *Nature.* 1999; 401:379–383. [PubMed: 10517636]
- Lindsay EA, Morris MA, Gos A, Nestadt G, Wolyniec PS, Lasseter VK, Shprintzen R, Antonarakis SE, Baldini A, Pulver AE. Schizophrenia and chromosomal deletions within 22q11.2. *Am J Hum Genet.* 1995; 56:1502–1503. [PubMed: 7762575]
- Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, Prampero T, Jurecic V, Ogunrinu G, Sutherland HF, Scambler PJ, et al. Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. *Nature.* 2001; 410:97–101. [PubMed: 11242049]
- Liu Q, Puche AC, Wang JB. Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS). *Neurochem Res.* 2008; 33:1263–1276. [PubMed: 18270824]
- Liu ZH, Smith CB. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. *Neurosci Lett.* 2009; 454:62–66. [PubMed: 19429055]
- Lochner C, Hemmings SM, Kinnear CJ, Nel D, Seedat S, Moolman-Smook JC, Stein DJ. Cluster analysis of obsessive-compulsive symptomatology: identifying obsessive-compulsive disorder subtypes. *Isr J Psychiatry Relat Sci.* 2008; 45:164–176. [PubMed: 19398820]
- Lodge D, Anis NA. Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. *Eur J Pharmacol.* 1982; 77:203–204. [PubMed: 7037432]
- Long JM, LaPorte P, Merscher S, Funke B, Saint-Jore B, Puech A, Kucherlapati R, Morrow BE, Skoultchi AI, Wynshaw-Boris A. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome. *Neurogenetics.* 2006; 7:247–257. [PubMed: 16900388]
- Long JM, LaPorte P, Paylor R, Wynshaw-Boris A. Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. *Genes Brain Behav.* 2004; 3:51–62. [PubMed: 14960015]
- Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. *AMA Arch Neurol Psychiatry.* 1959; 81:363–369.
- Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. *Proc Natl Acad Sci U S A.* 2004; 101:6033–6038. [PubMed: 15069197]
- Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH, Wihler C, Koliatsos VE, Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. *Proc Natl Acad Sci U S A.* 1999; 96:15239–15244. [PubMed: 10611369]
- Macbeth AH, Lee HJ, Edds J, Young WS 3rd. Oxytocin and the oxytocin receptor underlie intrasrain, but not interstrain, social recognition. *Genes Brain Behav.* 2009; 8:558–567. [PubMed: 19531157]
- Magara F, Ricceri L, Wolfer DP, Lipp HP. The acallosal mouse strain I/LnJ: a putative model of ADHD? *Neurosci Biobehav Rev.* 2000; 24:45–50. [PubMed: 10654660]
- Manent JB, Represa A. Neurotransmitters and brain maturation: early paracrine actions of GABA and glutamate modulate neuronal migration. *Neuroscientist.* 2007; 13:268–279. [PubMed: 17519369]
- Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin B, Nimgaonkar VL. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. *Genes Brain Behav.* 2006; 5:150–157. [PubMed: 16507006]
- Marin-Teva JL, Dusart I, Colin C, Gervais A, van Rooijen N, Mallat M. Microglia promote the death of developing Purkinje cells. *Neuron.* 2004; 41:535–547. [PubMed: 14980203]

- Marin JC, Moura PJ, Cysneiros RM, Colugnati DB, Cavalheiro EA, Scorza FA, Xavier GF, Zilbovicius M, Mercadante MT. Temporal lobe epilepsy and social behavior: an animal model for autism? *Epilepsy Behav.* 2008; 13:43–46. [PubMed: 18439879]
- Marrone MC, Marinelli S, Biamonte F, Keller F, Sgobio CA, Ammassari-Teule M, Bernardi G, Mercuri NB. Altered cortico-striatal synaptic plasticity and related behavioural impairments in reeler mice. *Eur J Neurosci.* 2006; 24:2061–2070. [PubMed: 17067303]
- Marsden CD. Which motor disorder in Parkinson's disease indicates the true motor function of the basal ganglia? *Ciba Found Symp.* 1984; 107:225–241. [PubMed: 6568150]
- Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet.* 2008; 82:477–488. [PubMed: 18252227]
- McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, Nestler EJ. Regulation of dopaminergic transmission and cocaine reward by the Clock gene. *Proc Natl Acad Sci U S A.* 2005; 102:9377–9381. [PubMed: 15967985]
- McGrath MJ, Campbell KM, Veldman MB, Burton FH. Anxiety in a transgenic mouse model of cortical-limbic neuro-potentiated compulsive behavior. *Behav Pharmacol.* 1999; 10:435–443. [PubMed: 10780249]
- McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ. Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. *Behav Neurosci.* 2008; 122:293–300. [PubMed: 18410169]
- Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. *J Neurosci.* 2007; 27:5546–5558. [PubMed: 17522300]
- Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofrontostriatal model revisited. *Neurosci Biobehav Rev.* 2008; 32:525–549. [PubMed: 18061263]
- Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry.* 2007; 64:543–552. [PubMed: 17485606]
- Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, Clair DM, Muir WJ, Blackwood DH, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. *Hum Mol Genet.* 2000; 9:1415–1423. [PubMed: 10814723]
- Mineur YS, Huynh LX, Crusio WE. Social behavior deficits in the Fmr1 mutant mouse. *Behav Brain Res.* 2006; 168:172–175. [PubMed: 16343653]
- Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. *Hippocampus.* 2002; 12:39–46. [PubMed: 11918286]
- Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, Sudhof TC. Alpha-neurexins couple Ca²⁺ channels to synaptic vesicle exocytosis. *Nature.* 2003; 423:939–948. [PubMed: 12827191]
- Miura K, Kishino T, Li E, Webber H, Dikkes P, Holmes GL, Wagstaff J. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. *Neurobiol Dis.* 2002; 9:149–159. [PubMed: 11895368]
- Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. *Cell.* 1999; 98:427–436. [PubMed: 10481908]
- Monteggia LM, Luikart B, Barrot M, Theobald D, Malkovska I, Nef S, Parada LF, Nestler EJ. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. *Biol Psychiatry.* 2007; 61:187–197. [PubMed: 16697351]
- Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, Engelmann M, Reul JM, Landgraf R, Holsboer F. Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. *J Neuroendocrinol.* 1995; 7:841–845. [PubMed: 8748120]

- Moretti P, Bouwknecht JA, Teague R, Paylor R, Zoghbi HY. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. *Hum Mol Genet.* 2005; 14:205–220. [PubMed: 15548546]
- Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, Antalffy B, Armstrong D, Arancio O, Sweatt JD, Zoghbi HY. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. *J Neurosci.* 2006; 26:319–327. [PubMed: 16399702]
- Moss J, Howlin P. Autism spectrum disorders in genetic syndromes: implications for diagnosis, intervention and understanding the wider autism spectrum disorder population. *J Intellect Disabil Res.* 2009; 53:852–873. [PubMed: 19708861]
- Moy SS, Perez A, Koller BH, Duncan GE. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. *Brain Res.* 2006; 1089:186–194. [PubMed: 16638606]
- Mukai J, Dhillia A, Drew LJ, Stark KL, Cao L, MacDermott AB, Karayiorgou M, Gogos JA. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. *Nat Neurosci.* 2008; 11:1302–1310. [PubMed: 18836441]
- Munakata K, Tanaka M, Mori K, Washizuka S, Yoneda M, Tajima O, Akiyama T, Nanko S, Kunugi H, Tadokoro K, et al. Mitochondrial DNA 3644T->C mutation associated with bipolar disorder. *Genomics.* 2004; 84:1041–1050. [PubMed: 15533721]
- Murphy DL, Uhl GR, Holmes A, Ren-Patterson R, Hall FS, Sora I, Detera-Wadleigh S, Lesch KP. Experimental gene interaction studies with SERT mutant mice as models for human polygenic and epistatic traits and disorders. *Genes Brain Behav.* 2003; 2:350–364. [PubMed: 14653307]
- Myers SM. Citalopram not effective for repetitive behaviour in autistic spectrum disorders. *Evid Based Ment Health.* 2010; 13:22. [PubMed: 20164519]
- Nakatani J, Tamada K, Hatanaka F, Ise S, Ohta H, Inoue K, Tomonaga S, Watanabe Y, Chung YJ, Banerjee R, et al. Abnormal behavior in a chromosome-engineered mouse model for human 15q11–13 duplication seen in autism. *Cell.* 2009; 137:1235–1246. [PubMed: 19563756]
- Naylor E, Bergmann BM, Krauski K, Zee PC, Takahashi JS, Vitaterna MH, Turek FW. The circadian clock mutation alters sleep homeostasis in the mouse. *J Neurosci.* 2000; 20:8138–8143. [PubMed: 11050136]
- Nestadt G, Samuels J, Riddle M, Bienvenu OJ 3rd, Liang KY, LaBuda M, Walkup J, Grados M, Hoehn-Saric R. A family study of obsessive-compulsive disorder. *Arch Gen Psychiatry.* 2000; 57:358–363. [PubMed: 10768697]
- Nichols CD, Roth BL. Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors. *Front Mol Neurosci.* 2009; 2:16. [PubMed: 19893765]
- Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL. Overview of genetics and obsessive-compulsive disorder. *Psychiatry Res.* 2009; 170:7–14. [PubMed: 19819022]
- Niculescu AB 3rd, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR. Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. *Physiol Genomics.* 2000; 4:83–91. [PubMed: 11074017]
- Nishiguchi N, Breen G, Russ C, St Clair D, Collier D. Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder. *Neurosci Lett.* 2006; 394:243–245. [PubMed: 16289783]
- Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR, Matzuk MM. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. *Proc Natl Acad Sci U S A.* 1996; 93:11699–11704. [PubMed: 8876199]
- Nomura Y. Early behavior characteristics and sleep disturbance in Rett syndrome. *Brain Dev.* 2005; 27(Suppl 1):S35–S42. [PubMed: 16182496]
- Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. *Mol Psychiatry.* 2002; 7:617–625. 524. [PubMed: 12140785]
- Nosyreva ED, Huber KM. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. *J Neurophysiol.* 2006; 95:3291–3295. [PubMed: 16452252]
- Nyabi O, Naessens M, Haigh K, Gembarska A, Goossens S, Maetens M, De Clercq S, Drogat B, Haenebalcke L, Bartunkova S, et al. Efficient mouse transgenesis using Gateway-compatible

- ROSA26 locus targeting vectors and F1 hybrid ES cells. *Nucleic Acids Res.* 2009; 37:e55. [PubMed: 19279185]
- O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome. *Hum Genet.* 2009; 126:3–12. [PubMed: 19521722]
- O'Roak BJ, State MW. Autism genetics: strategies, challenges, and opportunities. *Autism Res.* 2008; 1:4–17. [PubMed: 19360646]
- O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL. Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. *Neurosci Biobehav Rev.* 2007; 31:60–78. [PubMed: 16782199]
- Ogawa S, Kwon CH, Zhou J, Koovakkattu D, Parada LF, Sinton CM. A seizure-prone phenotype is associated with altered free-running rhythm in Pten mutant mice. *Brain Res.* 2007; 1168:112–123. [PubMed: 17706614]
- Ognibene E, Adriani W, Macri S, Laviola G. Neurobehavioural disorders in the infant reeler mouse model: interaction of genetic vulnerability and consequences of maternal separation. *Behav Brain Res.* 2007; 177:142–149. [PubMed: 17141885]
- Oitzl MS, Reichardt HM, Joels M, de Kloet ER. Point mutation in the mouse glucocorticoid receptor preventing DNA binding impairs spatial memory. *Proc Natl Acad Sci U S A.* 2001; 98:12790–12795. [PubMed: 11606764]
- Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. *J Psychiatr Res.* 1999; 33:523–533. [PubMed: 10628529]
- Oostra BA. Fragile X syndrome in humans and mice. *Acta Genet Med Gemellol (Roma).* 1996; 45:93–108. [PubMed: 8872018]
- Palo OM, Antila M, Silander K, Hennah W, Kilpinen H, Soronen P, Tuulio-Henriksson A, Kieseppa T, Partonen T, Lonnqvist J, et al. Association of distinct allelic haplotypes of DISC1 with psychotic and bipolar spectrum disorders and with underlying cognitive impairments. *Hum Mol Genet.* 2007; 16:2517–2528. [PubMed: 17673452]
- Pardo CA, Eberhart CG. The neurobiology of autism. *Brain Pathol.* 2007; 17:434–447. [PubMed: 17919129]
- Parker KJ, Buckmaster CL, Schatzberg AF, Lyons DM. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. *Psychoneuroendocrinology.* 2005; 30:924–929. [PubMed: 15946803]
- Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. *Behav Brain Res.* 2009; 204:313–321. [PubMed: 19136031]
- Paul LK, Brown WS, Adolphs R, Tyszka JM, Richards LJ, Mukherjee P, Sherr EH. Agenesis of the corpus callosum: genetic, developmental and functional aspects of connectivity. *Nat Rev Neurosci.* 2007; 8:287–299. [PubMed: 17375041]
- Pauls DL, Alsobrook JP 2nd, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. *Am J Psychiatry.* 1995; 152:76–84. [PubMed: 7802125]
- Paylor R, Lindsay E. Mouse models of 22q11 deletion syndrome. *Biol Psychiatry.* 2006; 59:1172–1179. [PubMed: 16616724]
- Pecina S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X. Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. *J Neurosci.* 2003; 23:9395–9402. [PubMed: 14561867]
- Pedersen CA, Vadlamudi SV, Boccia ML, Amico JA. Maternal behavior deficits in nulliparous oxytocin knockout mice. *Genes Brain Behav.* 2006; 5:274–281. [PubMed: 16594980]
- Pei Y, Dong S, Roth BL. Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution. *Curr Protoc Neurosci.* 2010; Chapter 4(Unit 4): 33. [PubMed: 20066658]
- Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. *Nature.* 1992; 355:725–728. [PubMed: 1741058]
- Phillips KA. The obsessive-compulsive spectrums. *Psychiatr Clin North Am.* 2002; 25:791–809. [PubMed: 12462861]

- Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. *J Med Genet.* 2004; 41:323–326. [PubMed: 15121767]
- Podhorna J, Didriksen M. The heterozygous reeler mouse: behavioural phenotype. *Behav Brain Res.* 2004; 153:43–54. [PubMed: 15219705]
- Polymeropoulos MH, Swift RG, Swift M. Linkage of the gene for Wolfram syndrome to markers on the short arm of chromosome 4. *Nat Genet.* 1994; 8:95–97. [PubMed: 7987399]
- Pooley EC, Fineberg N, Harrison PJ. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. *Mol Psychiatry.* 2007; 12:556–561. [PubMed: 17264842]
- Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, Daneels G, Bouwknecht JA, Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. *J Neurosci.* 2006; 26:9022–9029. [PubMed: 16943560]
- Puech A, Saint-Jore B, Merscher S, Russell RG, Cherif D, Sirotkin H, Xu H, Factor S, Kucherlapati R, Skoultschi AI. Normal cardiovascular development in mice deficient for 16 genes in 550 kb of the velocardiofacial/DiGeorge syndrome region. *Proc Natl Acad Sci U S A.* 2000; 97:10090–10095. [PubMed: 10963672]
- Qiu LF, Lu TJ, Hu XL, Yi YH, Liao WP, Xiong ZQ. Limbic epileptogenesis in a mouse model of fragile X syndrome. *Cereb Cortex.* 2009; 19:1504–1514. [PubMed: 18832330]
- Radyushkin K, Hammerschmidt K, Boretius S, Varoqueaux F, El-Kordi A, Ronnenberg A, Winter D, Frahm J, Fischer J, Brose N, et al. Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. *Genes Brain Behav.* 2009; 8:416–425. [PubMed: 19243448]
- Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. *Biol Psychiatry.* 2003; 53:352–359. [PubMed: 12586455]
- Rapoport JL, Addington A, Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us? *Curr Psychiatry Rep.* 2005; 7:81–82. [PubMed: 15802082]
- Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. *J Clin Psychiatry.* 1994; 55(Suppl):5–10. discussion 11–14. [PubMed: 7961532]
- Raud S, Sutt S, Luuk H, Plaas M, Innos J, Koks S, Vasar E. Relation between increased anxiety and reduced expression of alpha1 and alpha2 subunits of GABA(A) receptors in Wfs1-deficient mice. *Neurosci Lett.* 2009; 460:138–142. [PubMed: 19477223]
- Reichardt HM, Kaestner KH, Wessely O, Gass P, Schmid W, Schutz G. Analysis of glucocorticoid signalling by gene targeting. *J Steroid Biochem Mol Biol.* 1998; 65:111–115. [PubMed: 9699863]
- Reiss AL. Childhood developmental disorders: an academic and clinical convergence point for psychiatry, neurology, psychology and pediatrics. *J Child Psychol Psychiatry.* 2009; 50:87–98. [PubMed: 19220592]
- Ren-Patterson RF, Cochran LW, Holmes A, Lesch KP, Lu B, Murphy DL. Gender-dependent modulation of brain monoamines and anxiety-like behaviors in mice with genetic serotonin transporter and BDNF deficiencies. *Cell Mol Neurobiol.* 2006; 26:755–780. [PubMed: 17029036]
- Ren-Patterson RF, Cochran LW, Holmes A, Sherrill S, Huang SJ, Tolliver T, Lesch KP, Lu B, Murphy DL. Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. *J Neurosci Res.* 2005; 79:756–771. [PubMed: 15672416]
- Renner M, Choquet D, Triller A. Control of the postsynaptic membrane viscosity. *J Neurosci.* 2009; 29:2926–2937. [PubMed: 19261888]
- Rhodes JS, Garland T Jr, Gammie SC. Patterns of brain activity associated with variation in voluntary wheel-running behavior. *Behav Neurosci.* 2003; 117:1243–1256. [PubMed: 14674844]
- Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hortnagl H, Flor H, Henn FA, et al. Mice with genetically altered glucocorticoid receptor expression show altered

- sensitivity for stress-induced depressive reactions. *J Neurosci*. 2005; 25:6243–6250. [PubMed: 15987954]
- Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. *Eur J Pharmacol*. 2007; 571:25–28. [PubMed: 17618619]
- Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, Lechan RM, Jaenisch R. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. *Mol Endocrinol*. 2001; 15:1748–1757. [PubMed: 11579207]
- Rios M, Lambe EK, Liu R, Teillon S, Liu J, Akbarian S, Roffler-Tarlov S, Jaenisch R, Aghajanian GK. Severe deficits in 5-HT_{2A} - mediated neurotransmission in BDNF conditional mutant mice. *J Neurobiol*. 2006; 66:408–420. [PubMed: 16408297]
- Roberts SE, Dennis NR, Browne CE, Willatt L, Woods G, Cross I, Jacobs PA, Thomas S. Characterisation of interstitial duplications and triplications of chromosome 15q11–q13. *Hum Genet*. 2002; 110:227–234. [PubMed: 11935334]
- Robertson MM. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary. *Eur Child Adolesc Psychiatry*. 2006; 15:1–11. [PubMed: 16514504]
- Roussignol G, Ango F, Romorini S, Tu JC, Sala C, Worley PF, Bockaert J, Fagni L. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. *J Neurosci*. 2005; 25:3560–3570. [PubMed: 15814786]
- Roybal K, Theobald D, Graham A, DiNieri JA, Russo SJ, Krishnan V, Chakravarty S, Peevey J, Oehlein N, Birnbaum S, et al. Mania-like behavior induced by disruption of CLOCK. *Proc Natl Acad Sci U S A*. 2007; 104:6406–6411. [PubMed: 17379666]
- Sacco R, Militemi R, Frolli A, Bravaccio C, Gritti A, Elia M, Curatolo P, Manzi B, Trillo S, Lenti C, et al. Clinical, morphological, and biochemical correlates of head circumference in autism. *Biol Psychiatry*. 2007; 62:1038–1047. [PubMed: 17644070]
- Sadakata T, Mizoguchi A, Sato Y, Katoh-Semba R, Fukuda M, Mikoshiba K, Furuichi T. The secretory granule-associated protein CAPS2 regulates neurotrophin release and cell survival. *J Neurosci*. 2004; 24:43–52. [PubMed: 14715936]
- Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, Ohkura T, Katoh-Semba R, Nakajima M, Sekine Y, Tanaka M, et al. Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. *J Clin Invest*. 2007; 117:931–943. [PubMed: 17380209]
- Saeed SA, Bruce TJ. Seasonal affective disorders. *Am Fam Physician*. 1998; 57:1340–1346. 1351–1342. [PubMed: 9531916]
- Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. *Neuron*. 2001; 31:115–130. [PubMed: 11498055]
- Salinger WL, Ladrow P, Wheeler C. Behavioral phenotype of the reeler mutant mouse: effects of RELN gene dosage and social isolation. *Behav Neurosci*. 2003; 117:1257–1275. [PubMed: 14674845]
- Samaco RC, Hogart A, LaSalle JM. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. *Hum Mol Genet*. 2005; 14:483–492. [PubMed: 15615769]
- Samuels J, Shugart YY, Grados MA, Willour VL, Bienvenu OJ, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, et al. Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. *Am J Psychiatry*. 2007; 164:493–499. [PubMed: 17329475]
- Samuels JF, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Pinto A, Knowles JA, et al. The OCD collaborative genetics study: methods and sample description. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B:201–207. [PubMed: 16511842]
- Scattoni ML, McFarlane HG, Zhodzishsky V, Caldwell HK, Young WS, Ricceri L, Crawley JN. Reduced ultrasonic vocalizations in vasopressin 1b knockout mice. *Behav Brain Res*. 2008; 187:371–378. [PubMed: 18005969]

- Schindler KM, Richter MA, Kennedy JL, Pato MT, Pato CN. Association between homozygosity at the COMT gene locus and obsessive compulsive disorder. *Am J Med Genet.* 2000; 96:721–724. [PubMed: 11121168]
- Schnutgen F, Doerflinger N, Calleja C, Wendling O, Chambon P, Ghyselinck NB. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. *Nat Biotechnol.* 2003; 21:562–565. [PubMed: 12665802]
- Schroer RJ, Phelan MC, Michaelis RC, Crawford EC, Skinner SA, Cuccaro M, Simensen RJ, Bishop J, Skinner C, Fender D, et al. Autism and maternally derived aberrations of chromosome 15q. *Am J Med Genet.* 1998; 76:327–336. [PubMed: 9545097]
- Searle AG. New Mutants: Coloboma. *Mouse News Letters.* 1966; 2:27.
- Sgado P, Alberi L, Gherbassi D, Galasso SL, Ramakers GM, Alavian KN, Smidt MP, Dyck RH, Simon HH. Slow progressive degeneration of nigral dopaminergic neurons in postnatal *Engrailed* mutant mice. *Proc Natl Acad Sci U S A.* 2006; 103:15242–15247. [PubMed: 17015829]
- Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H. Mice with truncated *MeCP2* recapitulate many Rett syndrome features and display hyperacetylation of histone H3. *Neuron.* 2002; 35:243–254. [PubMed: 12160743]
- Sharp SI, McQuillin A, Gurling HM. Genetics of attention-deficit hyperactivity disorder (ADHD). *Neuropharmacology.* 2009; 57:590–600. [PubMed: 19715710]
- Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL, Chatzi C, He S, Mackie I, Brandon NJ, et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated *Discl1*. *J Neurosci.* 2008; 28:10893–10904. [PubMed: 18945897]
- Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: a more quantitative view. *Annu Rev Biochem.* 2007; 76:823–847. [PubMed: 17243894]
- Shmelkov SV, Hormigo A, Jing D, Proenca CC, Bath KG, Milde T, Shmelkov E, Kushner JS, Baljevic M, Dincheva I, et al. *Slitrk5* deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. *Nat Med.* 2010; 16:598–602. 591p following 602. [PubMed: 20418887]
- Siesser WB, Zhao J, Miller LR, Cheng SY, McDonald MP. Transgenic mice expressing a human mutant *beta1* thyroid receptor are hyperactive, impulsive, and inattentive. *Genes Brain Behav.* 2006; 5:282–297. [PubMed: 16594981]
- Sikora DM, Pettit-Kekel K, Penfield J, Merkens LS, Steiner RD. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. *Am J Med Genet A.* 2006; 140:1511–1518. [PubMed: 16761297]
- Simon HH, Thuret S, Alberi L. Midbrain dopaminergic neurons: control of their cell fate by the *engrailed* transcription factors. *Cell Tissue Res.* 2004; 318:53–61. [PubMed: 15340832]
- Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: A pregnant dam mouse model. *J Neuroimmunol.* 2009; 211:39–48. [PubMed: 19362378]
- Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. Altered anxiety-related and social behaviors in the *Fmr1* knockout mouse model of fragile X syndrome. *Genes Brain Behav.* 2005; 4:420–430. [PubMed: 16176388]
- Stark KL, Xu B, Bagchi A, Lai WS, Liu H, Hsu R, Wan X, Pavlidis P, Mills AA, Karayiorgou M, et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. *Nat Genet.* 2008; 40:751–760. [PubMed: 18469815]
- Stearns NA, Schaevitz LR, Bowling H, Nag N, Berger UV, Berger-Sweeney J. Behavioral and anatomical abnormalities in *MeCP2* mutant mice: a model for Rett syndrome. *Neuroscience.* 2007; 146:907–921. [PubMed: 17383101]
- Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENacles. *Int J Biochem Cell Biol.* 2009; 41:757–761. [PubMed: 18950730]
- Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. *Mol Psychiatry.* 2005; 10:900–919. [PubMed: 16027739]
- Strohle A, Poettig M, Barden N, Holsboer F, Montkowski A. Age- and stimulus-dependent changes in anxiety-related behaviour of transgenic mice with GR dysfunction. *Neuroreport.* 1998; 9:2099–2102. [PubMed: 9674601]

- Stuber GD. Dissecting the neural circuitry of addiction and psychiatric disease with optogenetics. *Neuropsychopharmacology*. 2010; 35:341–342. [PubMed: 20010708]
- Suzuki Y, Critchley HD, Rowe A, Howlin P, Murphy DG. Impaired olfactory identification in Asperger's syndrome. *J Neuropsychiatry Clin Neurosci*. 2003; 15:105–107. [PubMed: 12556580]
- Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. *Annu Rev Pharmacol Toxicol*. 2004; 44:269–296. [PubMed: 14744247]
- Swift M, Swift RG. Psychiatric disorders and mutations at the Wolfram syndrome locus. *Biol Psychiatry*. 2000; 47:787–793. [PubMed: 10812037]
- Swift RG, Sadler DB, Swift M. Psychiatric findings in Wolfram syndrome homozygotes. *Lancet*. 1990; 336:667–669. [PubMed: 1975860]
- Sykes NH, Toma C, Wilson N, Volpi EV, Sousa I, Pagnamenta AT, Tancredi R, Battaglia A, Maestrini E, Bailey AJ, et al. Copy number variation and association analysis of SHANK3 as a candidate gene for autism in the IMGSAC collection. *Eur J Hum Genet*. 2009; 17:1347–1353. [PubMed: 19384346]
- Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, Sudhof TC. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. *Science*. 2007; 318:71–76. [PubMed: 17823315]
- Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. *Proc Natl Acad Sci U S A*. 2005; 102:16096–16101. [PubMed: 16249339]
- Takeuchi M, Hata Y, Hirao K, Toyoda A, Irie M, Takai Y. SAPAPs. A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. *J Biol Chem*. 1997; 272:11943–11951. [PubMed: 9115257]
- Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT_{2c} serotonin receptors. *Nature*. 1995; 374:542–546. [PubMed: 7700379]
- Theiler K, Varnum DS. Development of coloboma (Cm/+), a mutation with anterior lens adhesion. *Anat Embryol (Berl)*. 1981; 162:121–126. [PubMed: 7283170]
- Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, Kratz L, Kelley RI. Abnormalities of cholesterol metabolism in autism spectrum disorders. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B:666–668. [PubMed: 16874769]
- Ting JT, Feng G. Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder. *Curr Chem Genomics*. 2008; 2:62–75. [PubMed: 19768139]
- Tissir F, Goffinet AM. Reelin and brain development. *Nat Rev Neurosci*. 2003; 4:496–505. [PubMed: 12778121]
- Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. *J Atten Disord*. 2009; 13:95–96. [PubMed: 19359667]
- Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R, Klein R, Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. *Nat Genet*. 1999; 23:99–103. [PubMed: 10471508]
- Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery R, Jaenisch R, Sur M. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. *Proc Natl Acad Sci U S A*. 2009; 106:2029–2034. [PubMed: 19208815]
- Tueting P, Costa E, Dwivedi Y, Guidotti A, Impagnatiello F, Manev R, Pesold C. The phenotypic characteristics of heterozygous reeler mouse. *Neuroreport*. 1999; 10:1329–1334. [PubMed: 10363948]
- Utomo AR, Nikitin AY, Lee WH. Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. *Nat Biotechnol*. 1999; 17:1091–1096. [PubMed: 10545915]
- van den Buuse M, Simpson ER, Jones ME. Prepulse inhibition of acoustic startle in aromatase knock-out mice: effects of age and gender. *Genes Brain Behav*. 2003; 2:93–102. [PubMed: 12884966]
- van West D, Van Den Eede F, Del-Favero J, Souery D, Norrback KF, Van Duijn C, Sluijs S, Adolfsson R, Mendlewicz J, Deboutte D, et al. Glucocorticoid receptor gene-based SNP analysis

- in patients with recurrent major depression. *Neuropsychopharmacology*. 2006; 31:620–627. [PubMed: 16192984]
- Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, Freed WJ. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. *Schizophr Res*. 2002; 58:11–20. [PubMed: 12363385]
- Veenstra-Vanderweele J, Jessen TN, Thompson BJ, Carter M, Prasad HC, Steiner JA, Sutcliffe JS, Blakely RD. Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse. *J Neurodev Disord*. 2009; 1:158–171. [PubMed: 19960097]
- Veltman MW, Craig EE, Bolton PF. Autism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic review. *Psychiatr Genet*. 2005; 15:243–254. [PubMed: 16314754]
- Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S. Object recognition impairment in *Fmr1* knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. *Behav Pharmacol*. 2004; 15:433–442. [PubMed: 15343070]
- Verbeek W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. *Adv Ther*. 2009; 26:170–184. [PubMed: 19238340]
- Wachtel H, Ahlenius S, Anden NE. Effects of locally applied dopamine to the nucleus accumbens on the motor activity of normal rats and following alpha-methyltyrosine or reserpine. *Psychopharmacology (Berl)*. 1979; 63:203–206. [PubMed: 113804]
- Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. *J Neurosci*. 2009; 29:3974–3980. [PubMed: 19339593]
- Wang X. Cre transgenic mouse lines. *Methods Mol Biol*. 2009; 561:265–273. [PubMed: 19504077]
- Wassink TH, Piven J, Vieland VJ, Huang J, Swiderski RE, Pietila J, Braun T, Beck G, Folstein SE, Haines JL, et al. Evidence supporting WNT2 as an autism susceptibility gene. *Am J Med Genet*. 2001; 105:406–413. [PubMed: 11449391]
- Wei Q, Lu XY, Liu L, Schafer G, Shieh KR, Burke S, Robinson TE, Watson SJ, Seasholtz AF, Akil H. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. *Proc Natl Acad Sci U S A*. 2004; 101:11851–11856. [PubMed: 15280545]
- Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD, Feliciano C, Chen M, Adams JP, Luo J, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature*. 2007; 448:894–900. [PubMed: 17713528]
- Welch JM, Wang D, Feng G. Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. *J Comp Neurol*. 2004; 472:24–39. [PubMed: 15024750]
- West L, Brunssen SH, Waldrop J. Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. *J Spec Pediatr Nurs*. 2009; 14:183–191. [PubMed: 19614827]
- Winslow JT, Insel TR. The social deficits of the oxytocin knockout mouse. *Neuropeptides*. 2002; 36:221–229. [PubMed: 12359512]
- Wolf SE, Woodside KJ. Transgenic and gene knock-out techniques and burn research. *J Surg Res*. 2005; 123:328–339. [PubMed: 15680397]
- Wood J, Birmaher B, Axelson D, Ehmann M, Kalas C, Monk K, Turkin S, Kupfer DJ, Brent D, Monk TH, et al. Replicable differences in preferred circadian phase between bipolar disorder patients and control individuals. *Psychiatry Res*. 2009; 166:201–209. [PubMed: 19278733]
- Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. *Psychol Med*. 2006; 36:1535–1540. [PubMed: 16907994]
- Xu X, Mill J, Sun B, Chen CK, Huang YS, Wu YY, Asherson P. Association study of promoter polymorphisms at the dopamine transporter gene in Attention Deficit Hyperactivity Disorder. *BMC Psychiatry*. 2009; 9:3. [PubMed: 19196467]
- Yamada T, Ishihara H, Tamura A, Takahashi R, Yamaguchi S, Takei D, Tokita A, Satake C, Tashiro F, Katagiri H, et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle

- progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. *Hum Mol Genet.* 2006; 15:1600–1609. [PubMed: 16571599]
- Yan J, Noltner K, Feng J, Li W, Schroer R, Skinner C, Zeng W, Schwartz CE, Sommer SS. Neurexin 1alpha structural variants associated with autism. *Neurosci Lett.* 2008; 438:368–370. [PubMed: 18490107]
- Yashiro K, Riday TT, Condon KH, Roberts AC, Bernardo DR, Prakash R, Weinberg RJ, Ehlers MD, Philpot BD. Ube3a is required for experience-dependent maturation of the neocortex. *Nat Neurosci.* 2009; 12:777–783. [PubMed: 19430469]
- Yin HH, Zhuang X, Balleine BW. Instrumental learning in hyperdopaminergic mice. *Neurobiol Learn Mem.* 2006; 85:283–288. [PubMed: 16423542]
- Yirmiya N, Rosenberg C, Levi S, Salomon S, Shulman C, Nemanov L, Dina C, Ebstein RP. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. *Mol Psychiatry.* 2006; 11:488–494. [PubMed: 16520824]
- Young WS 3rd, Shepard E, Amico J, Hennighausen L, Wagner KU, LaMarca ME, McKinney C, Ginns EI. Deficiency in mouse oxytocin prevents milk ejection, but not fertility or parturition. *J Neuroendocrinol.* 1996; 8:847–853. [PubMed: 8933362]
- Zhang F, Gradinaru V, Adamantidis AR, Durand R, Airan RD, de Lecea L, Deisseroth K. Optogenetic interrogation of neural circuits: technology for probing mammalian brain structures. *Nat Protoc.* 2010; 5:439–456. [PubMed: 20203662]
- Zhang F, Prigge M, Beyriere F, Tsunoda SP, Mattis J, Yizhar O, Hegemann P, Deisseroth K. Red-shifted optogenetic excitation: a tool for fast neural control derived from *Volvox carteri*. *Nat Neurosci.* 2008; 11:631–633. [PubMed: 18432196]
- Zhang H, Liu X, Zhang C, Mundo E, Macciardi F, Grayson DR, Guidotti AR, Holden JJ. Reelin gene alleles and susceptibility to autism spectrum disorders. *Mol Psychiatry.* 2002; 7:1012–1017. [PubMed: 12399956]
- Zhang J, Hou L, Klann E, Nelson DL. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. *J Neurophysiol.* 2009; 101:2572–2580. [PubMed: 19244359]
- Zhang W, Rohlmann A, Sargsyan V, Aramuni G, Hammer RE, Sudhof TC, Missler M. Extracellular domains of alpha-neurexins participate in regulating synaptic transmission by selectively affecting N- and P/Q-type Ca²⁺ channels. *J Neurosci.* 2005; 25:4330–4342. [PubMed: 15858059]
- Zhao S, Cunha C, Zhang F, Liu Q, Gloss B, Deisseroth K, Augustine GJ, Feng G. Improved expression of halorhodopsin for light-induced silencing of neuronal activity. *Brain Cell Biol.* 2008; 36:141–154. [PubMed: 18931914]
- Zheng WH, Quirion R. Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. *J Neurochem.* 2004; 89:844–852. [PubMed: 15140184]
- Zhong H, Serajee FJ, Nabi R, Huq AH. No association between the EN2 gene and autistic disorder. *J Med Genet.* 2003; 40:e4. [PubMed: 12525552]
- Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, Powell CM, Parada LF. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. *J Neurosci.* 2009; 29:1773–1783. [PubMed: 19211884]
- Zhou M, Rebholz H, Brocia C, Warner-Schmidt JL, Fienberg AA, Nairn AC, Greengard P, Flajolet M. Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. *Proc Natl Acad Sci U S A.* 2010; 107:4401–4406. [PubMed: 20145109]
- Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. *J Neurosci.* 2005; 25:4493–4502. [PubMed: 15872096]
- Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. *Proc Natl Acad Sci U S A.* 2001; 98:1982–1987. [PubMed: 11172062]

- Zoghbi HY. Postnatal neurodevelopmental disorders: meeting at the synapse? *Science*. 2003; 302:826–830. [PubMed: 14593168]
- Zuchner S, Cuccaro ML, Tran-Viet KN, Cope H, Krishnan RR, Pericak-Vance MA, Wright HH, Ashley-Koch A. SLITRK1 mutations in trichotillomania. *Mol Psychiatry*. 2006; 11:887–889. [PubMed: 17003809]
- Zuchner S, Wendland JR, Ashley-Koch AE, Collins AL, Tran-Viet KN, Quinn K, Timpano KC, Cuccaro ML, Pericak-Vance MA, Steffens DC, et al. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. *Mol Psychiatry*. 2009; 14:6–9. [PubMed: 19096451]

Table 1

Table of common behavior tests used to characterize animal models of childhood onset psychiatric disorders.

| Behavior Test | Description |
|--------------------------------|--|
| Anxiety/Fear: | |
| Active/Passive Avoidance | Measures the avoidance of an area where a foot shock was given. Passive avoidance required the mouse to not enter the area where the foot shock was presented. Active avoidance requires the mouse to exit the area where the foot shock was presented upon a cue. |
| Contextual Fear Conditioning | Measures the amount of freezing when placed in an environment where a previous negative stimulus (foot shock) was given |
| Elevated Plus Maze | Measures time spent in the open arm versus protected arm of a cross-shaped arena |
| Elevated Zero Maze | Measures time spent in the open area versus protected area of a circular arena |
| Light Dark Emergence | Measures latency to emerge from the dark chamber to the light chamber. Also measure total time spent in light and dark chambers, and activity levels in these chambers |
| Open Field | Measures time spent in the center of the open field arena versus the perimeter or corners of the arena |
| Reward/Aversion | Measures the latency to obtain a reward in the presence of an aversive stimulus (ex. predator urine, brightly lit novel arena) |
| Compulsive Behavior: | |
| Marble Burying | Measures the number of marbles buried as a result of compulsive digging or shifting in bedding |
| Non-nutritive Chewing | Measures amount of chewing of non-nutritive clay or substances |
| Repetitive Grooming | Measures number of grooming sessions and total time spent grooming in a 24 hour period. Also measures time spent grooming relative to other adaptive behaviors (eating, sleeping) |
| Depression: | |
| Learned Helplessness | Measures latency to escape a foot shock after repetitive training with foot shock in an inescapable chamber |
| Porsolt Forced Swim | Measures the time spent in vigorous swimming relative to the time spent floating in a tall cylinder filled with water |
| Tail Suspension | Measures the time spent struggling relative to the time spent immobile when suspended by the tail |
| Learning and Memory: | |
| Barnes Maze | Measures the ability to learn the location of an escape hole in a circular maze with 18 evenly spaced holes using spatial environmental cues |
| Morris Water Maze | Measures the ability to learn the location of a hidden platform using extra-maze spatial environmental cues |
| Radial Arm | Measures the number of entries into one of eight arms that are baited with food or water using spatial environmental cues; may tap into cognitive preservation |
| T Maze/Y-Maze | Measures the correct initial entry into an alternating arm of the maze baited with food or water using spatial environmental cues; may tap into cognitive preservation |
| Social Paradigms: | |
| Nest Building | Evaluates size and organization of nest building; may also assess procedural cognitive function |
| Pairing in Novel Environment | Measures amount of social approach of two mice paired in a novel environment |
| Resident Intruder | Measures amount of social approach when an intruder mouse is introduced into the home cage of the test mouse following social isolation |
| Social Approach-Partitioned | Measures amount of time spent near the partition dividing the test mouse from either a stranger or known mouse. |
| Social Approach- Three Chamber | Measures amount of time spent in an empty chamber versus a chamber containing a stranger mouse. Second trial measures the time spent in the chamber with a known mouse versus a stranger mouse versus an empty chamber |

| Behavior Test | Description |
|---|---|
| Social Recognition | Measures the amount of social interaction between the test mouse and a second mouse on the first and subsequent exposures |
| Ultrasonic Vocalization-Adults | Measures the number and duration of ultrasonic vocalizations of male mice exposed to female mice in estrous OR male mice during a resident intruder test |
| Ultrasonic Vocalization- Neonates | Measures the number and duration of ultrasonic vocalizations of pups during brief isolation from the dam and/or littermates |
| Other: | |
| Delayed Reinforcement | Measures the ability to wait for a preferred reinforcer (ex. water) over the immediately available less-preferred reinforce (ex. quinine). The time for the preferred reinforcer increases with each trial. |
| Reaction-Time Task | Measures the number of nose poke entries to receive a reward during a cued time period. |
| Home Cage Activity | Measures the amount of total, horizontal, and vertical activity in a home cage environment to test for habituation |
| Latent Inhibition | Measures the impaired performance during an active avoidance task when test training includes exposure to the cued stimulus but without any reinforcement contingencies |
| Open Field Activity | Measures the amount of total, horizontal, and vertical activity in a novel environment; other activities including stereotypic or repetitive patterns of movement can also be assessed |
| Pre-pulse Inhibition/Sensory Motor Gating | Measures the inhibition of a reflexive acoustic startle response to be inhibited when weaker stimuli are presented prior to the startle stimulus |
| Running Wheels | Measures the amount and duration of activity in a 24 hour period. Manipulation of light and dark cycles can allow for measuring circadian rhythm based on activity patterns over several months |